The role of LRRK2 in Parkinson’s disease : from function to dysfunction by Guerreiro, Patricia I. da Silva
Universidade de Lisboa 

















The role of LRRK2 in Parkinson’s disease: 
from function to dysfunction 
 
 







Doutoramento em Ciências Biomédicas 
Neurociências 
Dezembro de 2015 
	 	 	
Universidade de Lisboa 
















The role of LRRK2 in Parkinson’s disease: 
from function to dysfunction 
 
 
Patrícia I. da Silva Guerreiro 
 
 
Tese orientada por: Prof. Doutor Tiago Fleming Outeiro 
 




Todas as afirmações efectuadas no presente documento são da exclusiva 
responsabilidade do seu autor, não cabendo qualquer responsabilidade à 















































A impressão desta tese foi aprovada pelo Conselho Científico da 
Faculdade de Medicina de Lisboa em reunião de 26 de Maio de 
2015. 
	 	 	
Table of contents  
Acknowledgements …………………………………………………………… VI 
Abstract …………………………………………………………………………. VII 
Resumo …………………………………………………………………………. X 
List of abbreviations ………………………………………………………….. XIII 
Chapter 1. General Introduction   
  1. The neurodegenerative disorder of Parkinson’s disease ………………. 2 
     1.1 Clinical symptoms and pathogenesis of PD …………………………. 2 
     1.2 Etiology of PD …………………………………………………………… 4 
       1.2.1 Environmental factors ………………………………………………. 5 
       1.2.2 Genetic factors ………………………………………………………. 5 
     1.3. α-synuclein and PD ……………………………………………………. 7 
     1.4 Association of Tau with PD ……………………………………………. 9 
     1.5 Leucine-Rich Repeat Kinase 2: a key player in PD …….................. 10 
       1.5.1 Functional structure of LRRK2 protein …………………………… 11 
        1.5.2 LRRK2 mutations and PD …………………………...................... 12 
        1.5.3 Neuropathology of LRRK2 mutations in PD …………………….. 14 
        1.5.4 Interplay between GTPase and Kinase domains ……………….. 15 
        1.5.3 LRRK2 interacting proteins and putative functions …………….. 16 
     1.6 Cellular Quality Control Systems ……………………………………… 18 
        1.6.1 The ubiquitin-proteasome system (UPS) ………………………... 18 
        1.6.2 Autophagy ………………………………………………………....... 20 
     1.7 References ………………………………………………...................... 22 
Chapter 2. Aims of the project ……………………………………………… 28 
Chapter 3. LRRK2 interactions with α-synuclein in Parkinson’s 
                  disease brains and in cell models  
     3.1 Introduction and main goals …………………………………………… 30 
     3.2 Materials and Methods …………………………………………………. 31 
     3.3 Results …………………………………………………………………… 36 
        3.3.1 LRRK2 co-immunoprecipitates with α-synuclein ……………….. 36 
        3.3.2 LRRK2 co-localizes with α-synuclein in PD brain and cell  
                 model ………………………………………………………………… 37 
          3.3.3 Knocking down LRRK2 expression reduces α-synuclein 
               aggregation …………………………………………………………... 39 
        3.3.4 Increasing levels of LRRK2 correlates with α-synuclein in PD  40 
	 	 	
     3.4 Discussion ……………………………………………………………….. 42 
     3.5 References ………………………………………………………………. 46 
Chapter 4. LRRK2 promotes Tau accumulation, aggregation and 
release   
     4.1 Introduction and main goals …………………………………………… 49 
     4.2 Materials and Methods …………………………………………………. 50 
     4.3 Results …………………………………………………………………… 54 
       4.3.1 Tau levels are decreased in LRRK2 knock-out mice …………… 54 
       4.3.2 LRRK2 physically interacts with Tau ……………………………… 55 
       4.3.3 Increased levels of Tau depend on LRRK2 expression but not 
               on its kinase activity …………………………………………………. 56 
       4.3.4 LRRK2 promotes the accumulation of high-molecular weight      
               Tau species…………………………………………………………… 58 
       4.3.5 LRRK2 impairs proteasomal protein degradation independently 
               of its kinase activity………………………………………………… 60 
       4.3.6 LRRK2 impairs the proteasomal degradation of Tau but does 
             not interfere with the autophagy pathway ………………………… 62 
       4.3.7 LRRK2 promotes the cellular release of Tau …………………….. 62 
     4.4 Discussion ……………………………………………………………….. 64 
     4.5 References ………………………………………………………………. 68 
Chapter 5. LRRK2 interactors and their biological significance  
     5.1 Introduction and main goals …………………………………………… 71 
     5.2 Materials and Methods ………………………………………………… 71 
     5.3 Results …………………………………………………………………… 75 
       5.3.1 Network of protein interactions…………………………………….. 75 
       5.3.2 Gene Ontology Analysis ……………………………………………. 75 
       5.3.3 The effect of LRRK2 expression on the mechanical properties 
                of the cell……………………………………………………………… 81 
       5.3.4 Different LRRK2 distribution patterns result in different cell 
               stiffness ……………………………………………………………….. 81 
     5.4 Discussion ……………………………………………………………….. 84 
     5.5 References ………………………………………………………………. 87 
Chapter 6. General discussion and conclusions   
     6.1 The implications of interaction of LRRK2 with α-synuclein and Tau   90 
     6.2 LRRK2-interacting protein network and its particular role on 
          cytoskeleton dynamics ………………………………………………….. 93 
     6.3 Conclusions ……………………………………………………………... 94 
     6.4 References ………………………………………………………………. 96 
Chapter 7. Appendix ………………………………………………………….. 99 
	 	 VI	 	
Acknowledgements 
 During my PhD I was exposed to a variety of challenges, developing my 
passion for working in science and having the opportunity to meet amazing 
people, who became amazing friends. During this journey, I had the essential 
support of several people, which allowed me to grow and learn a lot on how to be 
a scientist and to whom I am extremely greatful. 
 I would like to thank my supervisor Prof. Dr. Tiago Outeiro, for taking me as 
a graduate student, for his support since the beginning of my project, for always 
being available to discuss my ideas and for encouraging me to work hard to 
achieve my goals. Also, for givinging me the opportunity to join the UNCM, at IMM 
in Lisbon, where I am proud to have been part of this extraordinary working group. 
Later on, for supporting my move to his group in Goettingen, allowing me to 
belong to an outstanding community of scientists.  
 I am thankful to all the members of UNCM group, that in one way or another 
helped me during my PhD. A very friendly thank to my colleagues and good 
friends: Teresa Pais, Leonor Fleming, Ana Oliveira, Oldriska Chutna, Elisa Basso, 
Sandra Jacinto, Hugo Miranda and Sandra Tenrreiro, with whom I shared fruitful 
scientific discussions and for the good moments and unconditional support in the 
lab. Also a special thank to Federico Herrera and Rita Oliveira for being so patient 
in helping me with the scientific writing, always with a very constructive criticism. 
 I would also like to thank all the members from the group in Göttingen, for 
receiving me so well, and having jointly started a new working group. I owe my 
gratitude to my german colleagues and good friends Ellen Gerhardt, Christiane 
Fahlbusch, Sonja Reisenauer and Omar Diaz, and to my special collaborator and 
friend Katrin Eckermann, for all the essential support, for always making my life 
easier, in and outside the lab, and for making me feel at home in the (sometimes) 
cold Germany. 
 A very special thank to my buddy Pauline, with whom I shared my time in 
Germany, for our long and hard hours in the lab, and also all the good moments 
outside the lab, and for always being with me in overcoming many Germans hills. 
 Lastly, I am extremely thankful to all my family for their unconditional 
support, in particular to João, for always supporting my life decisions, and to 
Mariana, for helping me to have a four-hand writing of this thesis. 
	 	 VII	 	
Abstract 
 
Parkinson’s disease (PD) belongs to the group of neurodegenerative 
disorders and it is currently considered the most common progressive movement 
disorder. Neurodegenerative disorders, such as Alzheimer’s, Huntington’s, fronto-
temporal dementia and amyotrophic lateral sclerosis, share several dysfunctional 
molecular pathways and impairments in basic cell mechanisms. Despite intense 
efforts to understand to decipherthe triggers underlying these disorders, to date, 
there is no effective cure. This results in a growing number of cases and, 
consequently, in a complex social and economic problem. Therefore, it is of 
extreme importance to understand the common biological mechanisms involved in 
the pathogenesis of this devastating group of diseases, in order to develop 
effective therapies. The majority of the PD cases are sporadic, however, in the last 
decades, it has been recognized that rare genetic mutations are patholgical for PD 
in a number of inherited cases. Futhermore, these mutations can be as well a risk 
factor for sporadic PD, supporting the idea that familial and sporadic PD can share 
common pathlogical mechanisms. 
This study focused on a key player protein in PD, Leucine-rich repeat kinase 
2 (LRRK2). Mutations in LRRK2 gene are the most frequent cause of autosomal 
dominant forms of PD and they are also consider a risck factor for sporadic cases. 
A central catalytic GTPase and kinase core, flanked by protein interaction 
domains, composes this large and complex multi-domain protein. The most 
frequent LRRK2 PD-related mutation occurs at the animoacid 2019, a glycine 
subtitution for a serine (G2019S), precisely on the kinase domain of the protein 
resulting in its toxic gain of function. LRRK2 is known to play a role in distinct 
cellular mechanisms such as vesicular trafficking, microtubule network regulation 
and mitochondrial morphology. However, the function of LRRK2 in these important 
mechanisms and their related pathways is not fully understood, which is crucial for 
developing new therapeutic targets. Here, we investigated LRRK2 function by 
characterizing/identifying its protein interactors and, in particular, by exploring its 
relationship with two central proteins in neurodegenerative disorders, α-synuclein 
and Tau. In PD brain samples, we show that levels of LRRK2 are positively 
correlated to an increase in α-synuclein phosphorylation and aggregation in 
affected brain regions, where both proteins co-localize in neurons and Lewy body 
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inclusions. In a cell line model, this co-localization also occurs in α-synuclein 
inclusions and knocking down LRRK2 promotes formation of smaller inclusions. 
Moreover, we show an interaction between α-synuclein and LRRK2 under 
endogenous and over-expression conditions. These results shed light on the 
complex interaction of these two central PD proteins and, in particular, on 
underlying molecular mechanisms involved in a disease scenario. Furthermore, 
we demonstrate that LRRK2 also interacts with Tau protein in a cell line model, in 
which co-expression of both proteins promotes accumulation of Tau protein. This 
accumulation occurs independently of LRRK2 kinase activity and it gives rise to 
formation of high molecular weight Tau species and increased levels of Tau 
secretion. Moreover, we suggest that these effects are a consequence of an 
impairment of proteasomal Tau degradation and that this impairment is promoted 
by LRRK2. Consistently, a LRRK2-knockout mouse displayed lower levels of Tau 
in the brain, when compared with transgenic animals expressing human wild-type 
LRRK2. Our results highlight the compromised status of cellular and molecular 
neurodegenerative mechanisms. The identification of LRRK2 interactors is crucial 
to placing the protein in known biochemical pathways. To that end, we performed 
a screen to identify LRRK2-interacting proteins. The results obtained confirmed 
that this is a multifaceted protein, involved in a variety of molecular functions and 
biochemical pathways. α-synuclein and Tau are two proteins present in the list of 
interactors, which validates previously reported results. The role of LRRK2 on the 
cytoskeleton is also highlighted by the presence of several protein interactors 
linked to microtubule dynamics, which lead us to explore the effect of LRRK2 on 
mechanical properties of the cell. Applying a combined microscopy tecniques in 
cell indentation experiments, we confirmed that different distribution patterns of 
LRRK2 result in differential states of cell stiffness. We found that the stiffest cells 
exhibit a diffuse pattern of LRRK2 distribution, such that LRRK2 is dispersed 
throughout the entire cell, interacting with microtubule-related proteins and 
compromising cytoskeletal dynamics. The identification of novel interactos resulted 
in a better understanding of LRRK2 patho-physiological role. 
Taken together, our results presented in this thesis provide novel insight into 
the function of LRRK2 and its particular role in neurodegenerative diseases. 
Ultimately, this knowledge is essential for the understanding of the molecular 
underpinnings of PD and for the development of novel therapeutics. 
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Resumo 
A doença de Parkinson (DP) pertence ao grupo das doenças 
neurodegenerativas, sendo atualmente considerada a doença neurodegenerativas 
motora progressiva mais comum. As doenças neurodegenerativas, como a 
doença de Alzheimer, a demência frontotemporal ou a esclerose lateral 
amiotrófica, partilham várias disfuncionalidades em importantes vias de 
sinalização molecular e mecanismos celulares. Apesar dos esforços 
desenvolvidos para compreender os factores que estão na origem e na 
progressão destas doenças, presentemente ainda não foi encontrada uma cura 
eficaz. O resultante crescente número de casos destas doenças, 
consequentemente contribui para um complexo problema socioeconómico. É 
assim de extrema importância identificar os mecanismos biológicos envolvidos na 
patogénese deste devastador grupo de doenças, a fim de desenvolver terapias 
eficazes para o combate das mesmas. A maioria dos casos de DP são 
esporádicos, no entanto nas últimas décadas têm sido identificadas várias 
mutações genéticas ligadas a casos hereditários. Estas mutações podem ainda 
ser consideradas um factor de risco para o desenvolvimento de casos 
esporádicos da DP, o que suporta a ideia que os casos hereditários e esporádicos 
partilham os mesmos mecanismos patológicos. 
Este estudo foca-se numa proteína chave na DP, Leucine-rich repeat kinase 
2 (LRRK2). Mutações na proteína LRRK2 são consideradas a causa mais 
frequente em casos autossómicos dominantes da doença, ocorrendo também em 
casos esporádicos. Esta grande e complexa proteína com múltiplos domínios, é 
composta por um núcleo catalítico central de GTPase e quinase, flanqueado por 
vários domínios de interação proteica. A mutação mais frequente em LRRK2 é a 
substituição de uma glicina por uma serina, que ocorre no aminoácido 2019 
(G2019S). Esta mutação localiza-se precisamente no domínio da quinase da 
proteína, promovendo um tóxico ganho de função da mesma. É conhecido o 
envolvimento de LRRK2 em distintos mecanismos celulares como o tráfego 
vesicular, regulação da rede de microtúbulos e morfologia mitocondrial. No 
entanto, não é completamente conhecido o papel de LRRK2 nestes importantes 
mecanismos e suas vias de sinalização, o que é crucial para o desenvolvimento 
de novos alvos terapêuticos. Neste trabalho investigamos a função de LRRK2 
através da caracterização/identificação de proteínas interatuantes, em particular 
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explorando a sua relação com duas proteínas centrais em doenças 
neurodegenerativas, alpha-sinucleína (α-sinucleína) e Tau. Em amostras de 
cérebro de pacientes com DP, mostramos que os níveis de LRRK2 são 
positivamente corelacionados com um aumento de fosforilaçao e agregação de α-
sinucleína fosforilada e agregada, nas regiões do cérebro mais afectadas. 
Também nas regiões de cérebro mais afectadas, se verifica uma co-localização 
destas duas proteínas em neurónios e em inclusões de corpos de Lewy. Num 
modelo de linha celular, esta co-localização também ocorre em inclusões de α-
sinucleína, onde o knockdown de LRRK2 promove a formação de inclusões mais 
pequenas. A interação entre α-sinucleína e LRRK2 é ainda confirmada em 
condições endógenas e de sobre-expressão. Estes resultados contribuem para 
uma melhor compreensão sobre a complexa interação destas duas proteínas 
centrais na DP, em particular sobre os mecanismos moleculares subjacentes, 
envolvidos num cenário de doença. Em seguida e usando um modelo celular, 
demostramos que a LRRK2 interatua com a Tau, sendo que a co-expressão 
destas proteínas promove uma acumulação de Tau. Esta acumulação ocorre 
independentemente da atividade de quinase da LRRK2, e promove a formação de 
espécies de Tau com elevado peso molecular, bem como um aumento de 
secreção de Tau. Estes efeitos serão a consequência de uma falha ao nível da 
degradação de Tau pelo proteassoma, que por sua vez será promovida pela 
LRRK2. Em cérebros de ratinhos knockout para LRRK2, verifica-se um 
decréscimo dos níveis de Tau, quando comparado com animais transgénicos para 
LRRK2 humana. Estes resultados realçam a disfunção de mecanismos celulares 
e moleculares, envolvidos nas doenças neurodegenerativas. A identificação de 
proteínas interatuantes com LRRK2 é crucial para posicionar esta proteína nas 
conhecidas vias de sinalização bioquímica. Com este objectivo, desenvolvemos 
um screen para identificar novas proteínas interatuantes com LRRK2. Os 
resultados obtidos confirmam que esta é uma proteína multifacetada, envolvida 
em várias funções moleculares e vias de sinalização bioquímicas. A presença de 
α-sinucleína e Tau nesta lista de proteínas interatuantes, vem validar os 
resultados acima descritos. Também a presença de várias proteínas relacionadas 
com a dinâmica de microtúbulos, vem realçar o papel de LRRK2 ao nível do 
citoesqueleto celular, o que nos levou a explorar o efeito de LRRK2 nas 
propriedades mecânicas das células. Aplicando uma técnica combinada em 
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microscopia celular, confirmámos que diferentes padrões de distribuição de 
LRRK2, resultam em diferentes estados de rigidez celular. Descobrimos que as 
células com maior rigidez são as que exibem um padrão difuso de distribuição de 
LRRK2, onde a proteína está dispersa por toda a célula, interagindo com 
proteínas relacionadas com os microtúbulos, comprometendo assim a dinâmica 
do citoesqueleto. A identificação de novas proteínas interatuantes resulta num 
melhor conhecimento da função pato-fisiológica de LRRK2. Em resumo, os 
resultados apresentados nesta tese, fornecem novos conhecimentos sobre as 
funções da LRRK2 e o seu particular papel nas doenças neurodegenerativas. Por 
fim, estes conhecimentos são essenciais para a compreensão das bases 
moleculares da DP e consequentemente para o desenvolvimento de novas 
terapêuticas. 
 
Palavras-chave: LRRK2, Doença de Parkinson, α-sinucleína, Tau, interação 
proteica. 
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Chapter 1. General Introduction 
 
1. The neurodegenerative disorder of Parkinson’s disease  
The earliest records about Parkinson’s disease date back to 1817 when a 
British surgeon, James Parkinson, described in the monograph “An Essay on the 
Shaking Palsy”, the first observations of patients affected by a disease he called 
“paralysis agitans”. Years later, the terminology was updated by a French 
neurologist, Jean-Martin Charcot, that in memory of James Parkinson, named this 
disorder Parkinson’s disease (PD).  
PD is the second most common progressive neurodegenerative disorder, 
affecting 1-2% of people over 65 years old and 4-5% above the age of 85. The 
onset of PD is intimately related with age, which increases the expected number of 
cases due to an increased lifespan of the population in developed countries [1,2]. 
Almost two centuries after the first descriptions of PD, and despite intense 
research efforts in the field, there is still no effective cure and our knowledge about 
the etiology and the development of this disease is still incomplete.  
The pathogenic mechanisms of PD, do not seem exclusive of this disease 
but actually share several common features with other neurodegenerative 
diseases like Alzheimer’s (AD), Huntington’s, fronto-temporal dementia and 
amyotrophic lateral sclerosis. Although these diseases present different features 
and hallmarks, they share several dysfunctional molecular pathways and 
impairments in basic cell mechanisms. Thus, it is very important to deeply 
investigate these common molecular pathways to determine the function of the 
key proteins. This cross knowledge is crucial to discover the basis of 
neurodegenerative mechanisms common to several dramatic diseases for 
targeting efficient therapies.	
	
1.1 Clinical symptoms and pathogenesis of PD 
PD is typically known for its characteristic motor symptoms such as resting 
tremor, bradykinesia, muscle rigidity and postural instability. Before the 
appearance of the first motor symptoms and the final diagnosis of the disease, 
there is already cognitive deterioration accompanied by pre-motor symptoms like 
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mood disturbances, rapid-eye-movement, sleep disorder, loss of smell (hyposmia) 
and depression [3,4].  
The described clinical symptoms result from an increasing and selective 
loss of dopaminergic neurons from a particular midbrain region, the substantia 
nigra pars compacta, and consequently a massive depletion of striatal dopamine, 
an extremely important neurotransmitter (Figure 1A and 1B).  Another typical 
pathological hallmark of PD, described in the early nineties by Friederich H. Lewy, 
is the presence of cytoplasmic protein-containing inclusions in the surviving 
dopaminergic neurons called Lewy bodies (LBs) (Figure 1C). LBs are 
agglomerates of several proteins, with α-synuclein being one of the major 
components and mostly present in the phosphorylated and fibrillar forms [3,5,6]. 
The presence of LBs is not only restricted to the dopaminergic neurons, they 
appear in other areas of the brain, such as spinal cord. Although considered a 
hallmark of PD, the LBs are also found in other neurodegenerative diseases like 
AD and Lewy body disease or even in healthy aged brains [7-9]. Curiously, 
patients with autosomal recessive forms of PD, in particular with mutations in the 
PARKIN gene, do not present LBs inclusions [10]. Despite the extensive research 
in the field, the question whether LBs confer toxicity or on the other hand are 
protective to the cells, by sequestering potential toxic species, is a hot topic for 
debate without a consensual answer [8,11,12]. 
 
 
Figure 1. Neuropathology of PD.  
Representation of a healthy brain (A) versus a 
PD brain (B). Highlighted in red are the 
compromised nigrostrital pathways and the 
depigmentation (three arrows), due to the loss 
of melanine present in the dying dopaminergic 
neurons, that projects to the striatum (putamen 
and caudate nucleus). (C) Detail of a Lewy 
body inclusion in dopaminergic neurons, 
showing the Immunoreactivity against α-
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 To date, there is no effective treatment to cure PD or stop the progressive 
degeneration of the dopaminergic neurons. While gene and stem cell therapies 
are being heavily studied and not yet available, the gold standart for the treatment 
of PD continues to be the pharmacological approached introduced in the eighties, 
aimed at amelioreating the motos symptoms of the disease. This therapy consists 
in the replacement of the depleted striatal dopamine by the administration of a 
dopamine percursor, L-3,4-dihydroxyphenylalamine, usually known as levodopa 
(L-dopa). Although it is considered an effective drug therapy for the motor 
symptoms, especialy when administered in early stages of the disease, L-dopa is 
not suitable for all PD cases and long-term treatment can promote severe side 
effects [13-15].  
Currently, PD is no longer exclusively considered a disorder of the 
dopaminergic neurons of the substantia nigra. Although its onset and progression 
are still unclear, the disease is thought to happen in different brain regions and 
even outside the nervous system [7,15,16]. The progressive and cumulative 
symptoms confirm that this is a multisystem disorder that needs to be approached 
from a broad perspective. 
 
1.2 Etiology of PD 
PD is a typical late onset disorder and most cases (90-95%) occur 
sporadically, without a defined cause or relation with patient’s life style, 
characterizing it as an idiopathic disease. It is consensual that the major risk factor 
for PD is ageing. However, initial finding linked the disease with environmental 
factors, such as the chronic exposure to several neurotoxic pesticides. Later on, in 
the late twenties, the discovery of rare familial genetic mutation linked with PD, 
brought a new perspective for the research of this disease. These findings leaded 
to the development of a variety of animal models, in attempt to elucidate the 
molecular pathogenesis of the disease [6,17].  Despite the increasing knowledge 
about the etiology and the development steps of PD, resulting from the intensive 
research in the field, the underlying molecular mechanisms of the disease are still 
not completely understood. 
Nowadays, there is solid evidence that a synergistic combination of 
environmental and genetic factors is determinant to the onset and development of 
the disease. 
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1.2.1 Environmental factors  
The first identified environmental factors for the development of PD was the 
continuous exposure to neurotoxins and chemical substances present in several 
pesticides. 6-hydroxydopamine was one of the first neurotoxins identified. It 
promotes a selective degeneration of the catecholaminergic neurons due to an 
increase in reactive oxygen species [18]. Another neurotoxin, MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine), was identified in a synthetic drug consumed by 
a group of drug addicts who started to develop typical parkinsonism symptoms. 
This neurotoxin crosses the blood brain barrier and is converted into MPP+ in glial 
cells, which then displays selective toxicity in dopaminergic neurons [19]. Also, the 
chronic exposure to pesticides widely used in agriculture, like rotenone and 
paraquat, were found to be a potential risk factor for PD. Rotenone inhibits the 
mitochondrial complex I promoting degeneration of nigral-striatal neurons. 
Paraquat directly crosses the blood brain barrier, contributes for an increase of 
reactive oxygen species, which lead to degeneration in dopaminergic neurons [20, 
21]. The knowledge about these neurotoxic chemicals was used to develop the 
first models of PD, which continue to be a valuable tool available for mimicking 
parkinsonism symptoms and consequently to test new therapeutics for impact on 
the disease [18]. 
Interestingly, there are some studies suggest that nicotine and caffeine 
contribute for a decrease in the incidence of PD [22], but these will not be explored 
further in this document, as it would be out of the scope. 	
 
1.2.2 Genetic factors 
In the last two decades, genome-wide studies in several populations 
identified a growing number of genes associated with familial PD, reinforcing the 
importance of genetics as a risk factor for the disease [23-25]. The regions of the 
genome to which these genes map are known as the PARK loci. In addition, 
several genes associated with non-familial forms of PD were identified (Table 1). 
The PARK loci correspond to genes that might be divided into two large groups: 
genes responsible for autosomal dominant or autosomal recessive forms of the 
disease [26,27].  
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Table 1. Genes and loci associated PD associated genes.   
AD: autosomal dominant; AR: autosomal recessive; LBs: Lewy bodies; JO: juvenile onset 
(age< 20); EO: early onset (age 20-40); Classic PD has a late onset (age >40). Adapted 
from [26] and [28]. 
 
Name Locus Gene Status of     inheritance Clinical phenotype 
PARK1 4q21-q23 SNCA AD Classic PD; with LBs 
PARK2 6q25-q27 PARKIN AR EO; without LBs 
PARK3 2p13 unknown AD Classic PD; with LBs 
PARK4 4q21 SNCA  (triplication) AD EO; with LBs 
PARK5 4p14 UCHL-1 AD Classic PD 
PARK6 1p36.12 PINK1 AR EO; with LBs 
PARK7 1p36.13 DJ1 AR EO; slow progression 
PARK8 12q12 LRRK2 AD Classic PD; heterogeneous pathology 
PARK9 1p36.13 ATP13A2 AR JO; Atypical-Kufor-Rakeb syndrome 
PARK10 1p32 unknown unclear Classic PD 
PARK11 2q37.1 GIGYF2 AD Classic PD 
PARK12 Xq21-q25 unknown unclear Classic PD 
PARK13 2p13.1 HTRA2 AD Classic PD 
PARK14 22q13.1 PLA2G6 AR EO; Parkinsonism-dystonia 
PARK15 22q12.3 FBXO7 AR JO; Parkinsonian pallidal syndrome 
PARK16 1q32 Rab7L1 unclear Classic PD 
PARK17 16q11.2 VPS35 AD Classic PD 
PARK18 3q27.1 EIF4G1 AD Classic PD 
PARK19 1p31.3 DNAJC6 AR JO parkinsonism 
PARK20 21q22.11 SYNJ1 AR EO 
-- 17q21.1 MAPT -- Fronto-temporal dementia 
-- 1q21 GBA -- Parkinsonism with LBs 
-- 5q23.1-q23.3 Synphilin-1 -- Classic PD 
-- 2q22-q23 NR4A2/Nurr1 -- Classic PD 
 
SNCA was the first gene associated with familial forms of PD. Although rare, 
missense mutations in SNCA such as A53T, A30P and E46K as well as 
duplications and triplications, are found in familial cases of PD [29-31]. New 
studies are constantly updating the SNCA mutations related with PD, and the most 
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recent ones described are: A53E, H50Q and G51D [32-35]. Also several 
polymorphisms in the SNCA gene can constitute risk factors for the development 
of sporadic PD [36,37]. 
Mutations in the LRRK2 gene are the most frequent cause of familial PD, 
although it is also associated with sporadic cases [38,39].  Several point mutations 
were identified within the multiple domains of the protein, however the G2019S 
substitution, in the catalytic core of the protein, is by far the most frequently 
identified [38].  
PARKIN, PINK1, DJ-1 and ATP13A2 are associated with autosomal 
recessive forms of PD, usually linked with juvenile and early-onset cases of the 
disease [27,40,41]. PARKIN mutations are responsible for the majority of the 
autosomal recessive PD cases, which interestingly are characterized by the 
absence of LBs [10]. 
 Although familial mutations are rare, present in only up to 10% of the cases, 
it is known that both familial and sporadic forms of PD share common pathogenic 
mechanisms, which are still not clear. Studying these mutated genes and their 
respective encoded proteins, to know more about their physiological functions and 
their dysfunction in PD, is crucial to identify molecular pathways that might be 
used as targets for therapeutic intervention. 
 
1.3 α-synuclein and PD 
The α-synuclein protein is the main component of LBs and LNs, present in 
different synucleinopathies. Importantly, mutations and multiplications in the SNCA 
gene (which encodes for α-synuclein) were the first known genetic causes 
associated with familial forms of PD [42, 43]. These facts make this protein a 
central player in PD and one of the most studied proteins in the field.  
α-synuclein is an abundant protein in the brain and it is particularly enriched 
in pre-synaptic terminals. Although its function is not completely understood, it 
appears to be involved in several cellular processes like synaptic activity, vesicle 
recycling and, as a chaperone it is involved in the formation of SNARE complexes 
[44, 45]. This small (140 amino acids), thermostable and natively unfolded protein 
is structurally composed of three different domains. The N-terminal region is 
usually unstructured in solution, forming amphipathic α-helices when it interacts 
with phospholipid membranes. The central non-amyloid-β component (NAC) is a 
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highly hydrophobic region, responsible for the amyloidogenic properties of the 
protein and the formation of β-sheet structures, which consequently potentiate 
aggregation. The C-terminus is a highly acidic region, and possibly responsible for 
the chaperone activity of the protein [46-48]. 
The first identified familial SNCA mutation was the A53T substitution, 
followed by two other point mutations A30P and E46K, all promoting early onset of 
the disease with an extremely aggressive progression [29-31]. While these 
mutations are considered rare, the duplications and triplications of wild-type SNCA 
are more prevalent and directly toxic via higher expression of the protein [36,37]. 
More studies are required to better characterize the recently described SNCA 
mutations (A53E, H50Q and G51D), which interestingly seem to be related with 
the aggregation capacity of the protein [32-35]. 
Familial mutations, multiplications, polymorphisms and post-translational 
modifications (particularly phosphorylation) of the protein are considered key 
factors contributing to α-synuclein accumulation and subsequent aggregation. As 
α-synuclein is such a predominant component of LBs, the mechanism through 
which this protein leads to aggregation and confers effects on onset and 
development of neurodegeneration, has been extensively studied [49-53]. Though 
α-synuclein is a monomeric and unfolded protein, its central hydrophobic region 
(NAC) has a tendency to oligomerize [54]. Briefly, the α-synuclein aggregation 
processes initiates with the formation of dimers that, due to a continuous 
oligomerization propensity, evolve into bigger oligomers, followed by protofibrils 
and amyloid fibrils, which ultimately are deposited in LBs. This aggregation 
process occurs together with neuronal dysfunction. However, there is an intense 
debate regarding which are the most toxic species formed along this pathway that 
contributes to an increase in cell toxicity, culminating in neuronal death [52-55]. To 
better understand this toxic oligomerization and aggregation process occurring in 
PD, it is also important to consider the relevance of several α-synuclein-interacting 
proteins. Synphilin-1 is a protein that co-localizes with α-synuclein in the LBs and 
is described to contribute to α-synuclein aggregation [56-58]. Some isoforms from 
the 14-3-3 chaperone-like protein family interact with genetic PD-associated 
proteins, including α-synuclein, and are present in the LBs from human PD 
patients [58-60]. 
Although several models were proposed to explain α-synuclein accumulation 
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and aggregation and its role in PD, this is not entirely known. This will be crucial to 
identifying therapeutic targets in an early phase, avoiding a massive neuronal 
death and disease progression. 
 
1.4 Association of Tau with PD 
The Tau protein is encoded by the microtubule-associated protein tau 
(MAPT) gene. There are six isoforms of the protein generated by alternative 
splicing [61]. This predominantly neuronal protein is highly expressed in the adult 
central nervous system, where it binds to and stabilizes microtubules. Tau 
interaction/stabilization with microtubules occurs through the C-terminal of the 
protein and is regulated by phosphorylation of specific epitopes, some of which 
have been described as pathogenic in some neurodegenerative disorders like AD 
and PD [62-64]. 
The Tau protein was initially related to AD, being one of the main 
components of neurofibrillary tangles, a defined pathological hallmark of the 
disease, together with extracellular plaques of amyloid-β peptides [65]. 
Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) 
was the first neurodegenerative disorder associated with Tau mutations, therefore 
belonging to the group of tauopathies [66]. Common to tauopathies, is the 
presence of hyperphosphorylated and insoluble aggregated forms of Tau, 
observed inside neuronal cells in different brain regions [67,68]. 
Several MAPT mutations were described to affect the ability of Tau to bind to 
microtubules and to increase its aggregation propensity. Moreover these 
mutations were recently confirmed by GWAS as a risk factor for PD [66, 69]. 
Further insight into the role of Tau as a key player in PD, can be gained from 
understanding how this protein interacts with the other two central PD proteins: α-
synuclein and LRRK2. 
The link between Tau and α-synuclein was first highlighted through the co-
occurrence of these proteins in insoluble protein deposits in PD and AD brains [70-
73]. In addition, it was shown that the majority of AD cases display some α-
synuclein enriched LBs and Tau tangles can, as well, be identified in PD brains 
[74-77]. In vivo studies confirmed the presence of hyper-phosphorylated Tau 
species in a mouse model of over-expressed α-synuclein [78]. In a Drosophila 
model of PD, the interaction between these two proteins resulted in the disruption 
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of cytoskeletal organization and increased neurotoxicity [79]. Moreover, in vitro 
studies show that α-synuclein and Tau are able to influence each other’s 
polymerization. In cell models, both proteins interact through GSK-3beta and Tau 
enhances α-synuclein aggregation and toxicity [80-82]. 
The link between Tau and LRRK2 is another interesting point that correlates 
Tau with PD. Being the most frequent cause of the autosomal dominant form of 
PD, LRRK2 cases are characterized by a pleomorphic pathology including LBs, 
LNs and Tau tangles [83,84]. Initial studies in a mutated LRRK2 mouse, showed 
an extensive Tau tangle pathology, and Tau positive axonal swellings were 
observed in rat neuronal cultures overexpressing a fragment of LRRK2 [85]. Years 
later, LRRK2 as a kinase, was suggested to phosphorylate Tau in a tubulin-
dependent manner [86]. Also in a mouse model of tauopathy, LRRK2 expression 
results in increased Tau aggregation and phosphorylation of different residues 
[87]. More recently in vitro studies demonstrate that this phosphorylation happens 
in the presence of tubulin and indirectly via GSK-3β [88]. 
 
1.5 Leucine-Rich Repeat Kinase 2: a key player in PD 
The human LRRK2 gene is located on chromosome 12 and encodes for a 
large protein named Leucine-rich repeat kinase (LRRK2). LRRK2 is also known as 
Dardarin, from the Basque word dardara (tremor), although this term is less used. 
The first LRRK2 mutations associated with PD were reported in 2004 and are 
currently considered the most common genetic cause of PD, being responsible for 
a high number (5-15%) of all familial cases [83,84]. Only a few mutations, 
concentrated at the enzymatic domains of the protein, segregate with familial 
disease. Importantly, there are several LRRK2 variants reported in all other 
domains of the protein, which are a risk factor for sporadic PD [89-90].  The 
G2019S mutation is the most frequently found in PD patients, and results in a 
kinase gain of function of the protein [91-93].  
Clinically, the symptomatology of LRRK2-related PD cases is 
indistinguishable from sporadic cases, presenting an average late onset with a 
slower progression and not frequently associated with dementia. The LRRK2-PD 
cases are characterized by a pleomorphic neuropathology with the presence of 
pure classical nigral neuronal degeneration or LBs, LNs and positive ubiquitin and 
Tau phosphorylated inclusions [94-95]. 
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The clinical and pathological similarity of LRRK2-related familial cases to 
sporadic cases, together with the identification of LRRK2 mutations as a common 
risk factor for sporadic PD cases, qualifies this protein as a candidate in bridging 
the gap between inherited and sporadic PD. Therefore, LRRK2 represents an 
extremely important target for research, with the potential to uncover the common 
mechanisms of familial and sporadic PD.  
 
1.5.1 Functional structure of LRRK2 protein 
LRRK2 is a multi-domain and large (2527 amino-acid) protein of 
approximately 285 kDa, expressed in various tissues including the brain. This 
multifunctional protein belongs to the Roco protein family, which is characterized 
by having a conserved domain containing a Ras-like GTPase domain, called ROC, 
and a characteristic COR domain (C-terminal of ROC). Neighbouring this GTPase 
domain is a serine/threonine kinase domain (Kinase), and together these two 
domains compose the central enzymatic core of LRRK2. Flanking these central 
core, the protein has additional protein-protein interaction domains such as 
ankirin-like repeats (ANK), leucine-rich repeats (LRRs) at N-terminal and a β-
propeller-like domain (WD40) at C-terminal (Figure 2) [38, 96].  
As a GTPase, LRRK2 binds GTP through its ROC domain, leading to a 
change of conformation and facilitating GTP hydrolysis. However, this GTPase 
activity is weaker when compared to other members of the Ras related GTPase 
family [97]. Several pathogenic mutations were found in the GTPase domain, 
located within the ROC (R1441G/C/H) and the COR (Y1699C) subdomains, which 
were associated with decreased GTPase enzymatic activity of the protein [98,99]. 
The kinase domain of LRRK2 shares a high similarity with mixed-lineage 
kinases (MLKs) and receptor-interacting protein kinases (RIPKs) [100]. Some of 
the studies to evaluate the kinase activity of LRRK2 are based on its capacity to 
phosphorylate myelin basic proteins (MBPs) like moesin and pseudo-substrate 
(single peptides or proteins) [101]. However, the most widely used assays to 
evaluate LRRK2 activity rely on its autophosphorylation capacity [102,103]. The 
most frequently reported mutation, G2019S, occurs precisely in the activation 
segment of the kinase domain and is responsible for a 2-3 fold gain-of-function of 
the protein. This point mutation is thought to interfere with the activated “ON-OFF” 
state of the kinase, due to the negative charge of the serine residue which 
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Figure 2. Domain organization of LRRK2 and cellular pathways associated with its 
function.  
Schematic representation of LRRK2 structural domains, highlighting the functional dimeric 
conformation of the protein. The protein has a central enzymatic core composed by a 
GTPase domain (ROC) and its C-terminal (COR), together with a serine/threonine kinase 
domain (Kinase). Flanking these central core, the protein has several protein-protein 
interaction domains; at N-terminal an ankirin-like repeats (ANK) and leucin-rich repeats 
(LRRs) and at C-terminal a β-propeller-like domain (WD40). In the central core of the 
protein are placed the most frequent and pathogenic mutations thought to be responsible 
for a decrease in GTPase activity and an increase of kinase activity. The study of LRRK2 
mutations has shed light on the protein function and on the cellular mechanisms where it 





1.5.2 LRRK2 mutations and PD 
Since the discovery of first LRRK2 mutations related with the autosomal 
dominant forms of PD, several other mutations have been identified within the 
multiple domains of the protein. Thus far, more than 40 LRRK2 variants have been 
reported, however only seven mutations are considered pathogenic: N1437H, 
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Among the LRRK2 mutations identified, G2019S is located in the kinase 
domain and promotes its gain of function, confirmed by increased phosphorylation 
of LRRK2 and known generic substrates [102].  G2019S is the most frequent 
mutation found in PD patients, being responsible for up to 7% of the familial cases 
and also 1-3% of sporadic cases worldwide [107]. The frequency of the G2019S 
mutation varies among different populations across the globe, being particularly 
high in genetically isolated populations where it can account for up to 40% of total 
PD cases [108].  A study with data collected from over 133 families, reported a 
higher occurrence of the G2019S mutation in southern than northern European 
countries [89].  The age-dependent penetrance of the G2019S mutation, results in 
a probability of disease onset of 28% at age 59, rising up to 74% at age 79 [107, 
109, 110]. Overall, the high but incomplete penetrance of G2019S mutation results 
in the existence of some carriers of the mutation, who do not develop PD in their 
lifetime [111, 112]. 
Neighbouring the G2019S, is the I2020T mutation, which seems to have a 
very modest effects on kinase activity of the protein, so the relationship of this 
mutation with the LRRK2 biochemical activities is unclear [113]. 
The three mutations, reported in the “hotspot” R1441 (R1414G/H/C), make 
this the second most common site of pathogenic LRRK2 substitutions. The 
R1441C mutation was initially founded in two autosomal dominant PD families. 
Although R1441C is found in different populations, R1414G is particularly common 
in the Basque region of Spain and R14141H was only found in four individual from 
diverse ethnicities [114].  These three mutations in the GTPase domain of LRRK2 
are generally associated with a decreased GTPase activity [115, 116]. In the COR 
domain, a tyrosine to cysteine or guanidine mutation (Y1699C) was reported in 
one family from UK and other family with German heritage [99]. These mutations 
present a highly variable penetrance and clinical features resemble the idiopathic 
PD cases, with a late onset of the disease. 
 The N1437H mutation, in the COR domain of LRRK2, is the most recently 
identified mutation, in a large Norwegian family, and curiously it presents a very 
young age of onset (approximately 48 year old) [117]. Interestingly other two 
LRRK2 polymorphisms (G2385R and R1628P), which are almost absent in 
Caucasians, represent almost 10% risk for sporadic PD in Asian populations [118, 
119]. 
                                                                                                                                             Chapter 1. 
	 14 
1.5.3 Neuropathology of LRRK2 mutation in PD 
The different LRRK2 mutations promote a wide spectrum of neuropathology 
features, resumed in table 2 [107]. The post-mortem analysis of LRRK2-
associated PD patients, revealed a pleomorphic neuropathology associated with 
different LRRK2 mutations and even within the same mutation. Indeed, the 
analysis of LRRK2-associated PD brains revealed a variety of pathological 
features consisting in a pure nigral neuronal degeneration, similar to classical PD 
cases, together with typical LBs and LNs [83,120,121]. There are also some cases 
were LBs and LNs are absent, but instead is displayed hyperphosphorylated or 
ubiquitinated single proteins, in particular Tau, indicative of frontotemporal 
dementia [122]. 
The presence of LBs is the most typical and widely spread pathological 
feature in LRRK2-associated PD cases, occurring in the brainstem, cortex and 
limbic system. Indeed, LRRK2 patients who bear the most frequent mutation 
(G2019S) mainly exhibit α-synuclein positive LBs pathology, which is a typical 
feature of idiopathic PD [107]. 
 
Table 2. Pathological features of LRRK2 mutations. 
Table representing the pleomorphic neuropathological features associated to the most 
frequent PD-LRRK2 mutations. Adapted from Lie J., et al, 2014 [107]. 
Mutation Protein domain Risk Ethnicity Neuropathology 
R1441C ROC Middle European 
LBs; NFTs 





SN neuronal loss 
Ubiquitin staining 
R1441H ROC ND Unknown 
Y1699C COR ND 
LBs; NFTs 
SN neuronal loss 
G2019S Kinase All population 
LBs; NFTs  
SN neuronal loss 
Ubiquitin staining 
I2020T Kinase ND 
LBs 
SN neuronal loss 
ND- not determined; LBs- Lewy bodies; LFTs- neurofibrillary tangles; SN- substantia nigra 
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The wide variety of pathological features associated with different LRRK2 
mutations, demonstrate that this protein influences different mechanisms of cell 
viability. The effect of LRRK2 mutations may still be conditioned by genetic 
variations of other loci such as MAPT or SNCA, which encodes for Tau and α-
synuclein, two other central proteins in neurodegeneration. The fact that LBs 
inclusions are a pathological feature common to LRRK2-related familial PD cases 
and sporadic cases, also highlight the importance of LRRK2 as a crucial protein to 
bridge the common features between idiopathic and familial PD pathology [112]. 
However, the characterization of LRRK2-associated neuropathology is still 
dependent on the systematic evaluation of large number of LRRK2 PD patients 
and respective families, in different populations. 
 
1.5.4 Interplay between GTPase and Kinase domains 
The central catalytic unit of LRRK2 confers to the protein a particular dual 
enzymatic activity: GTPase and kinase. Several lines of evidence suggest a 
potential intrinsic regulatory mechanism between these two domains [123-125].  
Interestingly, it is also in this ROC-COR-kinase catalytic core, where the most 
pathogenic and frequently observed LRRK2 mutations are found. In particular, the 
G2019S mutation at the kinase domain of LRRK2 is the most frequent mutation 
related with autosomal dominant forms of PD. The biological consequence of this 
glycine substitution for a serine has been extensively investigated, and the 
consensus is that it promotes an exacerbated increase in the kinase activity of the 
protein, resulting in neurological toxicity [126, 127].  Still, in the same kinase 
domain, the effect of the I2020T mutation is not well established. Contradictory 
results showing that this mutation promotes an increase, decrease or even a null 
effect on the kinase activity of the protein have been reported [128, 129]. The ROC 
domain of LRRK2, houses three different substitutions in the Arg1441 residue, 
R1441C/G/H, which appear to affect GTPase efficiency, leading to a decreased 
ability of LRRK2 to hydrolyze GTP [130-132]. These mutations are thought to alter 
the folding properties of the protein and, consequently, interfere with the known 
ability of LRRK2 to dimerise. This occurs due to the particular location of the 
R1441 residue, which might be responsible for disrupting the hydrogen bond 
between two GTPase domains [133, 134]. More recently, the Y699C mutation at 
the COR domain of LRRK2 has also been shown to affect the GTPase activity of 
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the protein [99].  This mutation causes a decrease in GTP hydrolysis by 
strengthening the interaction between the ROC-COR domains, which leads to a 
weaker bond between LRRK2 monomers. The described alterations on the 
GTPase activity of LRRK2 will also subsequently modulate the downstream kinase 
activity of the protein, in particular, by stimulating LRRK2 autophosphorylation 
[131,133,134]. Interestingly two mutations in the ROC domain of the protein, 
K1347A and T1348N, were described to totally abolish its kinase activity [134]. 
Moreover, the N and C-terminal of LRRK2 were suggested to act as modulators of 
its kinase activity. Thus, the N-terminus is suggested to have an inhibitory effect 
on kinase activity, while the C-terminal tail is required for full kinase activity [129, 
135].  Summing up, there are several LRRK2 mutations located within the GTPase 
and kinase domains of the protein, which reciprocally condition the double 
enzymatic activity of the protein and consequently, the downstream events. 
Therefore, the modulation of LRRK2 GTPase and kinase enzymatic activity is an 
appealing candidate for therapeutic intervention, aiming at preventing LRRK2-
dependent neuronal toxicity and progression of the disease [136-138].   
 
1.5.5 LRRK2 interacting proteins and putative function 
The complex multi-domain structure of LRRK2 encompasses a central 
GTPase and kinase core, flanked by additional putative protein interacting 
domains. These last domains suggest that LRRK2 may act as a scaffold protein 
involved in several signalling pathways and protein complexes. 
A number of in vitro screens revealed several potential LRRK2 substrates 
and/or interactor proteins, however their validation and biological meaning in in 
vivo models is not frequently achieved. To date, there are some identified and 
confirmed LRRK2 interactors that help to build a picture about the putative role of 
this complex multifunctional protein in several pathways and cellular mechanisms 
[139-142]. 
The potential role of LRRK2 in the cytoskeleton architecture and microtubule 
network dynamics was initially reported by the identification of 
ezrin/radixin/moesin, and β-tubulin, as LRRK2 substrates [101,143]. More 
recently, LRRK2 was reported to phosphorylate tubulin-associated Tau at the 
Thyrosine 181 residue, which may regulate neurite outgrowth, by promoting 
neurite retraction [86]. In the present thesis, we explored the biological 
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consequences of this interaction and proposed a mechanism through which 
LRRK2 regulates intracellular levels and Tau biochemical species by 
compromising Tau-proteasomal degradation (fully explored in Chapter 4). 
The structural similarity of LRRK2 with MLKs as well as the in vitro results 
showing its capacity to phosphorylate MKK3/6 and 4/7, suggest that this protein is 
upstream of the MAP kinase pathways. This idea is strongly supported by the in 
vivo results obtained in LRRK2 transgenic mice, where hyper-phosphorylation of 
MKK4 by the mutant G2019S, activates the MKK4-JNK-c-Jun pathway, leading to 
degeneration of dopaminergic neurons [144]. Studies in a Drosophila 
melanogaster revealed that LRRK2 phosphorylates the transcription factor FoxO1 
at Ser319. It is known that this phosphorylation promotes an enhancement of 
transcriptional activity, triggering a cascade of mechanisms, like oxidative stress 
and programed cell death. However, other direct downstream targets are poorly 
identified [145].  
The ADP-ribosylation factor GTPase-activating protein 1 (ArfGAP1) was also 
identified as a robust substrate of LRRK2. The two proteins interact in vivo in the 
brain and co-localize at Golgi membranes. ArfGAP1 regulates LRRK2 GTPase 
activity and thereby modulate its kinase activity. Moreover, in primary cortical 
neurons, silencing of ArfGAP1 expression rescues the neurite shortening 
phenotype induced by LRRK2-G2019S, and neurite shortening induced by 
ArfGAP1 overexpression is also attenuated by silencing of LRRK2 [146]. 
The role of LRRK2 in the synaptic environment was highlighted by the 
discovery of EndophilinA (EndoA) as a LRRK2 substrate. EndoA is a crucial 
protein involved in the vesicle formation during the endocytosis process [147]. 
When LRRK2 is phosphorylated at serine 75, it inhibits the role of EndoA on 
membrane tubulation, increasing its affinity to bind to membranes and so 
compromising synaptic vesicle endocytosis [148]. α-synuclein is another synaptic 
protein that was initially reported to be a LRRK2 substrate [149]. Although this idea 
was very appealing, the biological meaning of this interaction was not further 
explored. More recently, we reported that α-synuclein interacts LRRK2 [150]. In 
Chapter 3, we fully explore how LRRK2 models α-synuclein aggregation pattern in 
vitro, showing they co-localize in neurons and LBs.  
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1.6 Cellular Quality Control Systems 
The misfolding and accumulation of certain proteins is a pathology hallmark 
common to several neurodegenerative disorders, where it could act as an 
underlying cause of the disease mechanism [151]. In fact, the accumulation of 
misfolded proteins leads to the formation of intermediate oligomeric species and, 
ultimately, protein aggregates. Whether these protein aggregates promote a toxic 
or a defensive effect on the cells remains a topic of intense debate in the field 
[152].  Neurons, as post-mitotic cells with a high metabolic activity, are extremely 
sensitive to protein accumulation. Thus, the post-mortem confirmation of the 
presence of protein aggregates in the brain of patients with neurodegenerative 
diseases emphasises the importance of protein turnover in neuronal homeostasis. 
To avoid the deleterious process of protein accumulation, cells have specific 
quality control mechanisms wish include molecular chaperons, the ubiquitin-
proteasome system (UPS) and autophagy.  While chaperons help other proteins in 
the folding process, the UPS and autophagy are responsible for the targeting and 
degradation of unfolded or mutated proteins. The degradation of proteins is critical 
to clear the cytosolic space, from proteins that might be harmfull for essential 
cellular processes, and also to recycle amino acids. Impairment in the cell quality 
control mechanisms is usually related with neurodegenerative diseases and 
therefore the focus of intensive research in the field [153]. 
 
1.6.1 The ubiquitin-proteasome system (UPS)  
The UPS is responsible for the degradation of misfolded, mutated and 
excess cytoplasmic short-lived proteins. Protein substrates are tagged with a poly-
ubiquitin chain and targeted for proteasomal degradation (Figure 3). This complex 
mechanism depends on a cascade of enzymatic events involving specific proteins 
for the degradation of a substrate. This mechanism requires the involvement of 
ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2) and protein-
ubiquitin ligase (E3). These enzymes specifically recognize the substrates, 
covalently attach multiple ubiquitin molecules, which will make the protein 
recognized and degraded by the 26S subunit of the proteasome [151, 155].  
The PARKIN and UCH-L1 genes encode two proteins associated with 
familial forms of PD (Table 1). These two proteins play roles in the UPS. Parkin is 
a typical ubiquitin ligase enzyme (E3) and UCHL-1 is an ubiquitin carboxyl-
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terminal esterase, involved in deubiquitylation and the recycling of ubiquitin [156, 
157]. Mutations in these PD-related genes, as well as exposure to stressful 
environmental conditions impair the UPS, leading to the accumulation of protein 
aggregates and intermediary protein species, detrimental for neuronal survival 
[151-155]. By itself, proteolytic stress caused by large amounts of non-degraded 
proteins also inhibits the regular function of the UPS. This creates a vicious cycle 
that alters the regular mechanism of protein degradation, leading to continuous 

























Figure 3. Cellular Quality Control Systems. 
Schematic representation of the ubiquitin proteasome system (UPS), chaperone mediated 
autophagy (CMA) and macroautophagy. Native and misfolded protein can be targeted 
with a poly-ubiquitin chain to be degraded by the proteasome (UPS) or even a chaperon 
protein that lead them to be degraded in the lysosome (CMA). Protein inclusions and 
bigger aggregates are engulfed in a phagophore that after merged with a lysosome, 
results in an autophagosome, characterizing the macroautophagy process.  
 
 
The UPS activity decreased in aged neurons. Accordingly, age-related 
impairment of the proteasomal activity is implicated in several neurodegenerative 
diseases [153]. Moreover, the presence of highly ubiquitylated protein inclusions in 
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different neurodegenerative diseases, suggests that impairment of protein 
degradation might be a common feature of these disorders [151,158].   
Thus, being the UPS an essential protein quality control mechanism, 
disturbances on its function might lead to pathological conditions, such as those 
occurring in neurodegenerative disorders as PD and AD. However the exact 




Autophagy is another cellular quality control mechanism, responsible for the 
clearance of cytosolic components, in lysosomes. Its importance in the central 
nervous system has been emphasized in recent years [159]. Macroautophagy, 
microautophagy, and chaperone mediated autophagy (CMA) are the three types of 
autophagy co-existing in animal cells, which differ depending on the size of the 
cargo delivered to the lysosomes. Both macroautophagy and microautophagy 
involve the direct sequestration of the cytosolic cargo. In macroauthophagy, this 
sequestration happens by a vacuole that seals to form a double-membraned 
vesicle (autophagosome). In microauthophagy, the cargo sequestration happens 
by invaginations at the lysosomal membrane. The CMA does not involve 
sequestration of cytosolic cargo, which instead is selectively recognised by a 
complex of chaperones that mediates its delivery to a receptor at the lysosomal 
membrane (Figure 3) [159,160].  This translocation process is limited to soluble 
proteins that are able to be completely unfolded. Nowadays, the important role of 
autophagy in neural cells is well accepted and there is evidence confirming the 
altered autophagy in major neurodegenerative disorders. This is especially due to 
accumulation of autophagic vesicles in multiple diseased-brains and particularly in 
SNpc neurons from PD patients [161]. 
There are also genes related to familial forms of the disease, which are 
directly involved in autophagy, such as the ATP13A2, that encodes for a 
transmembrane lysosomal protein [162]. 
As already mentioned, age is the most important risk factors for 
neurodegenerative disorders. Interestingly, with ageing there is an impairment of 
the protein degradation mechanisms, leading to protein accumulation that 
gradually contributes to an imbalance in protein homeostasis. Consequently, this 
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results in inadequate response to stress, increased toxicity and overall reduced 
cell lifespan, which comprise the basis of neurodegenerative diseases [153,163]. 
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Aims of the project 
 
Parkinson’s disease is a disorder, with causes and mechanisms still not 
completely known and, consequently, without a definitive cure. However, the study 
of PD-related gene mutations became a major focus to understand the underlying 
mechanisms of the disease in order to develop efficient therapeutics.  
To date, mutations in the LRRK2 gene are considered to be the most 
common genetic cause of PD. Several studies have unveiled the high degree of 
complexity of this multi-tasking protein. Despite the different clues about the 
cellular mechanisms in which LRRK2 might be involved, the function of this protein 
and its role in PD-associated neurodegeneration remains unclear.  
In order to gain insight into both the normal function of LRRK2 and also into its 
role in PD, our goals were to: 
 
1. Explore the relation between LRRK2 with another central PD-related 
protein, α-synuclein (Chapter 3) 
1.1 Investigate the interaction of LRRK2 with α-synuclein using cell models 
and also in PD brain samples. 
1.2 Evaluate the effect of LRRK2 on α-synuclein aggregation using a cell 
model of α-synuclein aggregation.  
 
2. Understand the effect of LRRK2 and its kinase activity on Tau protein 
(Chapter 4) 
2.1 Evaluate the effect of LRRK2 on Tau intra- and extra-cellular levels  
2.2 Clarify important cellular mechanisms where LRRK2 could be involved 
in compromising Tau accumulations and the cellular consequences of this 
effect. 
 
3. Identify novel LRRK2-interacting proteins and the molecular pathways 
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Chapter 3. LRRK2 interactions with α-synuclein in Parkinson’s 
disease brains and in cell models 
 
3.1 Introduction and main goals 
Parkinson’s disease (PD) is the most common neurodegenerative 
movement disorder resulting from the loss of dopamine neurons in the substantia 
nigra and the abnormal deposition of cytoplasmic inclusions known as Lewy 
bodies (LBs) and Lewy neuritis (LNs) in widespread regions of the brain [1]. The 
aetiology of PD is multifactorial, with a growing number of genetic abnormalities 
identified [2]. The first PD causative gene was α-synuclein (SNCA), which encodes 
for the presynaptic protein α-synuclein [3]. Rare patients have missense mutations 
(A53T, A30P, and E46K) or multiplications of SNCA [2], but all PD patients 
accumulate phosphorylated α-synuclein in the form Lewy pathologies [4,5]. 
Leucine-rich repeat kinase 2 (LRRK2) has been identified as the second and more 
common gene responsible for autosomal-dominant PD [6-9]. The function of the 
large LRRK2 protein remains unclear, although its serinethreonine/tyrosine kinase 
function is considered most important for PD etiology due to the occurrence of the 
most common LRRK2 mutation (G2019S) in this domain [2]. As phosphorylation of 
α-synuclein is central to PD and the most common autosomal-dominant mutation 
occurs in a kinase, there has been intense debate about whether α-synuclein 
physically interacts with LRRK2 and whether it might be one of its substrates [10]. 
However, to date, only one report has shown that α-synuclein interacts with, and is 
phosphorylated by, LRRK2 and only under pathological and non-physiological 
oxidative stress conditions [11]. Co-immunoprecipitation is the gold standard for 
assessing direct protein interactions but relies on antibody specificity, a previous 
problem for LRRK2 antibodies that has been recently solved with the aid of 
resources from the Michael J. Fox Foundation (MJFF). It is now possible to revisit 
the question of a LRRK2 and α-synuclein interaction using these new and well-
characterized LRRK2 antibodies. The aim of the present study was to establish 
whether LRRK2 and α-synuclein interact in human brain samples and to 
investigate the significance of the interaction in cell models. We report a molecular 
interaction between LRRK2 and α-synuclein under endogenous and over-
expression conditions. We show in affected PD brain regions that the amount of 
LRKK2 protein is increased in association with increasing levels of phosphorylated 
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α-synuclein. At the neuronal level, we confirm co-localization of LRRK2 and α-
synuclein in LBs in PD patients and show co-localization in a cell model of α-
synuclein inclusion formation. In addition, knockdown of LRRK2 in this cell model 
increases the number but reduces the size of α-synuclein inclusions. Altogether, 
our data provide strong evidence for an interaction between LRRK2 and α-
synuclein in PD and opens novel avenues for the investigation of the interplay 
between different PD genes and their exploitation as targets for therapeutic 
intervention. 
 
3.2 Materials and methods 
Human and mouse brain samples 
Human brain tissue was obtained from the Sydney Brain Bank and the 
NSW Tissue Resource Centre as part of the Australian Brain Bank Network 
funded by the National Health and Medical Research Council of Australia 
(NHMRC) with appropriate institutional ethics approvals. Frozen brain tissue 
samples and formalin-fixed paraffin-embedded tissue sections from different brain 
regions considered to be progressively affected by α-synuclein deposition in PD 
[12] were received from ten sporadic PD cases and ten matched controls 
(Appendix Table 3.1). The regions were the amygdala (affected pre-clinically in 
PD), the midbrain and anterior cingulate cortex (affected when symptoms are 
apparent) and the visual cortex (remains free of α-synuclein pathology even at end 
stage disease). Crude soluble human brain proteins were extracted from the 
frozen tissue as previously described [13]. Briefly, tissue was homogenized with a 
pre-chilled dounce homogenizer using ice-cold tris-buffered saline (TBS, pH7.4) 
lyses buffer (LB) containing protease and phosphatase inhibitor cocktails (Roche, 
Dee Why, Australia and Thermo Fisher Scientific, Waltham, MA, USA). The TBS-
soluble supernatant fraction was collected after centrifugation at 16,000×g for 25 
min at 4 °C, and the pellets were solubilized in LB containing 5 % SDS (SDS-
soluble fraction). Protein concentration was measured using a Nanodrop1000 
(Thermo scientific) for all samples. Ethics approval for the human tissue studies 
was from the University of New South Wales Human Research Ethics Committee. 
Frozen mouse brain samples from LRRK2 knockout C57BL/6J adult mice 
and age-matched controls were kindly provided by Dr. Mark Cookson and Dr. 
Iakov Rudenko (NIH (NIA), Bethesda, MD, USA). Mouse brain tissue was lysed in 
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RIPA buffer (25 mM Tris–HCl pH7.6; 150 mM NaCl; 0.1 % SDS; 1 % NP40) 
supplemented with protease and phosphatase inhibitor cocktails (Roche 
diagnostics, Mannheim, Germany) using a mechanic homogenizer. Lysates were 
incubated in a rotor for 1 h at 4 °C and then sonicated. Following centrifuge 
separation (at 10,000×g for 10 min at 4 °C), the supernatants were kept and total 
protein concentration quantified using BCA assay (Thermo Fisher Scientific, 
Rockford, IL, USA). 
 
Immunoprecipitation and western blot analyses 
Immunoprecipitation experiments were performed using 1 mg (cells) or 6 
mg (brain) of total protein. Lysates were pre-cleared by incubation with 20 µl of 
protein G beads (Invitrogen, Barcelona, Spain) for 30 min at 4 °C in rotation. 
Supernatants were recovered and incubated with 2 µg of the corresponding 
immunoprecipitation antibody: anti-α-synuclein (C-20, Santa Cruz Biotechnologies, 
Santa Cruz, CA, USA), anti-Myc (Cell Signaling, Danvers, MA, USA) or anti-
LRRK2 (c41-2 MJFF), followed by overnight rotation at 4 °C. The next day, 40 µl 
of protein G beads were added for 3 h in a rotator at 4 °C. Beads were washed 5× 
with immunoprecipitation buffer, then re-suspended in 20 µl of protein sample 
buffer (50 mM Tris–HCl pH6.8; 2 % SDS; 10 % glycerol; 1 % β-mercaptoethanol; 
0.02 % bromophenol blue) and boiled at 95 °C for 5 min. Supernatants were 
resolved on 12 % SDS-PAGE gels. Proteins were transferred overnight to 
nitrocellulose membranes and blocked in 5 % non-fat dry milk in TBS-Tween for 1 
h. The membranes were incubated overnight at 4 °C with the primary antibodies 
using the following dilutions: anti-α-synuclein (syn-1, BD Biosciences, San Jose, 
CA, USA, 1:1,000), anti-Myc (Cell Signaling, Danvers, MA, USA, 1:4,000) and 
anti-LRRK2 (c41-2 MJFF, 1:1,000). Immunoblots were washed with TBS-Tween 
and incubated for 1 h at room temperature with the corresponding HRP-labelled 
secondary antibody (GE Healthcare, Bucks, UK, 1:10,000). Immunoreactivity was 
visualised by chemiluminescence using an ECL detection system (Millipore, 
Billerica, MA, USA) and subsequent exposure to autoradiographic film. Standard 
Western blotting was used to assess the relative amounts of LRRK2 [14] and α-
synuclein [15] in 25 µg of the TBS-soluble protein from human brain samples com- 
pared with β-actin (loading control). The following primary antibodies were used: 
LRRK2 (c41-2, MJFF, 1:1,000), anti-α-synuclein (syn-1, BD Biosciences, San 
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Jose, CA, USA, 1:2,000), anti-S129 phosphorylated α-synuclein (Elan 
Pharmaceuticals Inc. [16], 1:10,000 or WAKO, Richmond, VA, USA, 1:10,000) and 
anti-mouse β-actin (Sapphire Biosciences, Waterloo, Australia, 1:10,000). LRRK2 
protein was separated on precast NuPAGE 3–8 % gradient Tris–acetate gels 
(Invitrogen, Carlsbad, CA, USA) with constant voltage of 150 V for 50 min, and 
transferred onto polyvinylidene difluoride membranes (BioRad Laboratories, 
Hercules, CA, USA) at 30 V constant for 2 hours. α-synuclein and S129 
phosphorylated α-synuclein was separated on 12 % SDS- PAGE gels with 
constant voltage of 100 V for 90 min, and transferred onto 0.22-µm nitrocellulose 
membranes (Bio- Rad Laboratories, Hercules, CA, USA) at 75 V constant for 45 
min. To normalise the data between the different gels, the same control sample 
was loaded on all gels and probed for β-actin in addition to the proteins of interest. 
Immunoreactivity was visualised by chemiluminescence using an ECL detection 
system (GE Healthcare Biosciences, Pittsburgh, PA, USA) and the intensity of 
each band quantified using ImageJ software (http://rsbweb.nih.gov/ij/) with the 
relative expression normalised to the β-actin of the internal standard. Multivariate 
linear regression analysis (SPSS IBM, New York, NY, USA) was used to identify 
any differences in protein levels between groups and regions, and linear 
regression modelling (SPSS IBM, New York, NY, USA) was used to determine if 
LRRK2 and α-synuclein protein levels were related to each other and could predict 
group status. Age and post-mortem interval were cofactored into all analyses. The 
mean difference and standard error are given for all values. 
 
Routine cell culture, plasmids and transfections 
Both wild-type (WT) and G2019S forms of LRRK2 plasmids (pCMV-Tag3B-
2xMyc-LRRK2, a kind gift from Dr. Mark Cookson, NIH (NIA), Bethesda, MD, 
USA) and WT pSI-α-synuclein plasmids (a kind gift from Dr. Bradley Hyman, 
Massachusetts General Hospital, USA) were used to over-express proteins for co-
immunoprecipitation experiments. 
Human embryonic kidney 293 cells (HEK-293) were cultured in DMEM 
media (Invitrogen, Barcelona, Spain) supplemented with 10 % fetal bovine serum 
and 1 % penicillin-streptomycin in 5 % CO2 at 37 °C. One day before transfection 
1.5×106 cells were seeded in 10 cm plates. Cells were transiently transfected 
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using a total of 6 µg of plasmid DNA using FuGENE®6 (Roche diagnostics, 
Mannheim, Germany). Forty-eight hours later, cells were washed with PBS, 
harvested in immunoprecipitation buffer supplemented with protease and 
phosphatase inhibitors and sonicated. Lysates were centrifuged at 10,000×g for 
10 min at 4 °C. Pellets were discarded and the total protein concentration of the 
supernatants quantified using BCA assay (Pierce). 
 
α-Synuclein aggregation model in H4 cells 
A gene construct encoding for tagged version of α-synuclein (SynT, a kind 
gift from Dr. Bradley Hyman, Massachusetts General Hospital, US) was co-
transfected with the synphilin-1 into H4 cells to recreate Lewy body-like inclusions, 
as previously described [17]. Briefly, H4 cells were cultured in OPTIMEM media 
(Gibco, Invitrogen, Barcelona, Spain) supplemented with 10 % of fetal bovine 
serum and 1 % of penicillin-streptomycin in an atmosphere of 37 °C and 5 % CO2. 
Twenty-four hours before the transfection, 2.0×105cells were seeded in a 35 cm 
dish (Ibidi, Munich, Germany). Cells were transfected with 2 µg of each synphilin-1 
and SynT plasmids using FuGENE®6 (Roche diagnostics, Mannheim, Germany). 
After transfection, cells were maintained for 48 h prior to further manipulations. H4 
cells with reduced LRRK2 expression were created using lentiviral particles 
encoding LRRK2 shRNAs or a control scramble shRNA sequence (Appendix 
Table 3.2) and the model for α-synuclein inclusions (described above) recreated in 
H4-LRRK2 knockdown cell lines. 
 
Confocal microscopy in cells and tissue sections 
LRRK2 and α-synuclein localization was performed in human tissue 
sections of the midbrain and anterior cingulate cortex and in transfected H4 cells 
with and without shRNA knockdown of LRRK2 expression. In the human tissue 
sections, both routine peroxidase immunohistochemistry and double 
immunofluorescence were performed. In H4 cells, single and double 
immunofluorescence was performed.  
Adjacent human sections were pre-treated with 99 % formic acid for 3 min 
and citrate buffer (pH6.0) for 3 min, then incubated sequentially with anti-LRRK2 
(MJFF c41-2, 1:200 and L955 Abgent, 1:500), anti-α-synuclein (BD Biosciences, 
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San Jose, CA, USA, 1:200) and anti-S129 phosphorylated α-synuclein (Elan 
Pharmaceuticals Inc. [16], 1:10,000) antibodies, biotinylated secondary antibodies 
(anti-mouse IgG for α-synuclein and anti-rabbit IgG for LRRK2; Vector, 
Burlingame, CA, USA), and then the avidin-biotin complex (Vectastain Elite ABC 
Kit, Vector, Burlingame, CA, USA) prior to visualization with DAB substrate 
(Sigma, St. Louis, MO, USA) in 0.1 % H2O2. Sections were counterstained with 
cresyl violet. LRRK2 and α-synuclein were co-localized in human sections and the 
H4 cell α-synuclein aggregation model using double immunofluorescence. Briefly, 
cells were washed, fixed with 4 % PFA, permeabilized with 0.5 % Triton, blocked 
with 1.5 % normal goat serum, then incubated in anti-α-synuclein (BD 
Biosciences, San Jose, CA, USA, 1:1,000) and anti-LRRK2-2 (MJFF c41-2, 1:50) 
antibodies, while human sections were pre-treated as above and incubated with 
anti-α-synuclein (BD Biosciences, San Jose, CA, USA, 1:200) and anti-LRRK2 
(L955 Abgent, 1:500) antibodies or with anti-S129 phosphorylated α-synuclein 
(Elan, 1:10,000) and anti-LRRK2 (L955 Abgent, 1:500) antibodies. Then, a cocktail 
of secondary antibodies was used: for α-synuclein and S129 phosphorylated α- 
synuclein anti-mouse IgG conjugated with Alexa Fluor 488 (Molecular probes, 
Eugene, OR, USA, 1:500) and for LRRK2 anti-rabbit IgG conjugated with Alexa 
Fluor 568 (Molecular Probes, 1:250). Fluorescent images were captured either 
using a Nikon Microscope ECLIPSE 90i confocal microscope (for human tissue 
sections) or using a Leica Microsystems confocal microscope (for H4 cells). The 
proportion of neurons in the human brain sections that co-localized LRRK2 and α-
synuclein was quantified in each section (total number of LRRK2 positive 
neurons/the total number of α-synuclein positive neurons]) and double labeling of 
LBs assessed (average number sampled/ section varied from 1 to 63, depending 
on the region assessed). Pearson correlation coefficients were used to determine 
whether there was any relationship between the numbers of LBs containing α-
synuclein and those also containing LRRK2 in the PD cases examined. 
Quantification of the aggregation pattern of α-synuclein inclusions in H4 cells was 
performed. Briefly, for each condition (control and LRRK2-KD), a total of 40–60 
cells containing α-synuclein inclusions were analyzed, and a total of three 
independent experiments were performed. Cells were classified into two groups: 
cells with <5 inclusions and cells with ≥5 inclusions, and the results were 
expressed as a percentage of the total number of cells with inclusions. The 
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Disclaimer: The presented results with human brain samples were performed by 
Yue Huang from Neuroscience Research Australia and the University of New 
South Wales. 
  
3.3.1 LRRK2 co-immunoprecipitates with α-synuclein  
In order to investigate the interaction between LRRK2 and α-synuclein, we 
used mouse brain samples from WT and LRRK2 knockout animals. The 
immunoprecipitation of α-synuclein from mouse brain lysates pulled down LRRK2 
in WT samples, but not in knockout samples (Figure 1A). We also verified the 
interaction between LRRK2 and α-synuclein when the immunoprecipitations were 
performed in human brain lysates. 
In order to investigate whether LRRK2 mutations alter the interaction with 
α-synuclein, we over-expressed WT or G2019S mutant LRRK2 together with α-
synuclein in HEK-293 cells. Immunoprecipitation of LRRK2 from cells over-
expressing Myc-LRRK2 (WT or G2019S mutant) together with α-synuclein pulled 
down α-synuclein (Figure 1B).  
Consistently, when α-synuclein was immunoprecipitated, the LRRK2 proteins 
(WT and G2019S) were also co-immunoprecipitated (Figure 1C). We did not find 
significant alterations in the pattern of co-immunoprecipitation between WT and 
G2019S mutant, indicating that the interaction between the two proteins is not 
disturbed by this mutation.  
In order to map the interaction between LRRK2 and α-synuclein, we express 
several Flag-LRRK2 constructs together with α-synuclein. After an 
immunoprecipitation of α-synuclein we could verify that the co-immunoprecipitation 
with LRRK2 only occurs in the first two constructs (Figure 1D). This result 
































Figure 1. Co-immunoprecipitation of LRRK2 and α-synuclein. A Western blots 
showing the immunoprecipitation of endogenous α-synuclein in lysates from WT and 
LRRK2 knockout mouse brains. The co-immunoprecipitation with endogenous LRRK2 
occurs in WT but not in the LRRK2 knockout brain sample. B, C Over-expression of Myc-
LRRK2 (WT or G2019S) together with α-synuclein in HEK-293 cells showed the co-
immunoprecipitation of LRRK2 (WT or G2019S) with α-synuclein. Using anti-Myc as the 
capture antibody and anti-α- synuclein and anti-LRRK2 antibodies for Western blotting (B) 
or using anti-α-synuclein as the capture antibody and anti-α-synuclein and anti-Myc 
antibodies for Western blotting (C). D Over-expression of Flag-tagged LRRK2 constructs 
together with α-synuclein in HEK-293 cells. Immunoprecipitating α-synuclein with a 
specific antibody, is showed the co-immunoprecipitation with LRRK2 constructs number 1 
and number 2, using a anti-Flag antibody. 
 
3.3.2 LRRK2 co-localizes with α-synuclein in PD brain and cell model  
PD brain samples were examined to determine whether LRRK2 and α-
synuclein or phosphorylated α-synuclein were co-localized. We found that LRRK2 
increases along with α-synuclein in neurons prior to LB formation (Figure 2A) as 
well as depositing in some but not all of the hallmark inclusions (Figure 2B-D).  







































Figure 2. Co-localization of LRRK2 and α-synuclein in PD brain and cell models. In 
PD brains (A-D, F-G), merged images clearly outline single neurons in the substantia 
nigra (A, B) and LBs (B-D, F-G) using double labelling immunofluorescence. There is an 
increase of LRRK2 and α-synuclein immunoreactivity in brainstem neurons without Lewy 
body formation (A), with LRRK2 co-localizing with α-synuclein in LBs (donut inclusion in 
B) in these neurons. The co-localization of LRRK2 and α-synuclein was also observed in 
cortical LBs (C). Cortical LBs without LRRK2 immunoreactivity were also observed (D). 
S129 phosphorylated α-synuclein antibody also confirmed co-localisation of LRRK2 with 
phosphorylated α-synuclein, with LRRK2 often centralized to a radiating pattern of 
phosphorylated α-synuclein fibrils (F-H). In the H4 cell model, double-labelling 
immunofluorescence for α-synuclein inclusion formation shows that endogenous LRRK2 
co-localizes with α-synuclein inclusions (E). Scales in all panels are equivalent to 10 µm. 
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LRRK2 was also observed in phosphorylated α-synuclein-immunoreactive 
inclusions, often centralized to a radiating pattern of phosphorylated α-synuclein 
fibrils (Figure 2F,H). Quantitation of the numbers of α-synuclein inclusions 
immunopositive for LRRK2 in ten PD cases indicates that 60 % of cingulate LBs 
and 43 % of nigral LBs contained both proteins (Figure 2B-C). The specificity of 
the co-localization can be taken as genuine, as no 280kDa LRRK2 band was 
detected on Western blot and no immunoreactivity in tissue sections in peptide 
pre-absorption experiments. There was no correlation between the number of α-
synuclein-positive LBs and those also containing LRRK2 across the cases 
examined. We also interrogated an in vitro model that reproduces the formation of 
α-synuclein inclusions in H4 cells [17]. Using this model, we observed co-
localization of endogenous LRRK2 with the α-synuclein-positive inclusions (Figure 
2E). 
 
3.3.3 Knocking down LRRK2 expression reduces α-synuclein aggregation 
To further investigate the effect of LRRK2 on α-synuclein aggregation, 
LRRK2 expression was knocked down using shRNAs in the H4 cell model. 
Knocking down LRRK2 expression did not produce significant changes in 
endogenous α-synuclein or phosphorylated α-synuclein levels (Figure 3A). 
Transiently transfecting these LRRK2-deficient cells with SynT and synphilin-1 
expression plasmids showed that LRRK2 silencing significantly increased the 
number and decreased the size of α-synuclein inclusions resulting in a greater 
number of cells bearing smaller α-synuclein inclusions (Figure 3B-D).  
 
3.3.4 Increasing levels of LRRK2 correlates with α-synuclein in PD  
To explore the relationship between protein levels of LRRK2 and α-
synuclein in PD, 20 cases (controls and Braak PD stages IV and V, Appendix 
Table 3.1) were analyzed. Multivariate analysis factoring in age and post-mortem 
delay showed that the levels of total and phosphorylated α-synuclein were 
significantly increased over control levels only in PD brain regions with LBs (p < 
0.001). In the cases examined, all stage IV cases had high LB densities in the 
amygdala (Figure 4A), while significant densities of cingulate LBs were observed 
in all stage V cases (Figure 4B). No LBs were seen in the visual cortex of any 
case, although very small-phosphorylated deposits were observed in stage V 
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cases (Figure 4C). 
 
Figure 3. Knockdown of LRRK2 
expression alters the size and 
number of α-synuclein inclusions. 
(A) Western blots showing that H4 
cells infected with LRRK2-shRNA 
have the expected knockdown of 
LRRK2 protein (LRRK2-KD) compared 
with the scramble shRNA control, but 
have no significant change on the level 
of endogenous α-synuclein or 
phosphorylated α-synuclein at S129. 
(B) The model for α-synuclein 
inclusions was reproduced in a LRRK2 
knockdown cell line and in parental 
control cells. Cells were classified into 
two groups according to the number of 
α-synuclein-immunoreactive inclusions 
observed: cells with five or more 
inclusions and cells with less than five 
inclusions. Scale bar=10µm. (C) Data 
from three independent experiments 
shows a greater proportion of cells 
containing five or more inclusions in 
the LRRK2 knockdown cells compared 
with controls. (D) LRRK2 silencing 
(LRRK2-KD) promotes a significant 
reduction in the average size of the 
inclusions, resulting in a more 
punctate aggregation pattern in the 




In PD, there was a substantial 220±20 % increase over controls in α-
synuclein protein levels in the amygdala and a less substantial 48±6 % increase in 
the cingulate cortex, with no change in the visual cortex (Figure 4D, E). This 
pattern of regional increase in α-synuclein levels was even more striking when 
assessing phosphorylated α-synuclein protein levels (p=0.01), as very low levels 
of phosphorylated α-synuclein were observed across all regions in controls 
compared to PD (Figure 4E).  












Figure 4. Increased levels of total and S129 phosphorylated α-synuclein in PD brain. 
A-C Peroxidase immunohistochemistry of brain sections from the same PD case showing 
the regional density of Lewy pathology as revealed by immunohistochemistry using 
phosphorylated α-synuclein antibody and counterstained with cresyl violet. Scale in C= 
100 µm and is equivalent for A and B. Severe pathology is observed in the amygdala (A) 
with moderate pathology in the anterior cingulate cortex (B). Neuronal inclusions are not 
observed in the visual cortex (C). D and E Quantitation (D) of Western blots (E) in the 
same three brain regions in the PD cases (represented as an increase over control levels) 
confirmed the regional changes noted histologically in PD and showed considerably more 
phosphorylated α-synuclein compared with total α-synuclein in each regions (note the 
percentage at left versus fold change at right in D). Error bars=SEM. 
 
 
There was a very large 60±18 fold increase in phosphorylated α-synuclein 
protein levels in the PD amygdala, a 32±4 fold increase in the PD cingulate cortex 
and an 8±3 fold change in the PD visual cortex relative to controls (Figure 4D,E). 
The expression of LRRK2 was analyzed using the same methods in the 
same brain extracts (Figure 5). Multivariate analysis co-varying for age or post-
mortem delay showed that the levels of LRRK2 were increased in PD compared 
with controls in regions containing LBs (p<0.04), with no difference between the 
LRRK2 levels in these Lewy body-containing regions (p=0.6). Within these 
regions, there was a small but significant 23±6 % increase over controls in full-
length LRRK2 levels (Figure 5A,B). 
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To determine the relationship between LRRK2 and α-synuclein levels and PD, 
linear regression modeling was used assessing the protein levels obtained in the 
amygdala and cingulate cortex.  
This analysis revealed that increasing levels of LRRK2 and total and 
phosphorylated α-synuclein correlated with each other in PD but not controls 





Figure 5. LRRK2 levels correlated with 
α-synuclein levels in PD brain. 
Quantitation (A) of LRRK2 Western blots 
(B) in the same brain regions in the PD 
cases (represented as an increase over 
control levels) and correlations with α-
synuclein levels (C). The protein levels of 
LRRK2 were increased in the disease-
affected areas (amygdala and cingulate) 
compared to the non-affected area (visual 
cortex) (A). Error bars=SEM. Multivariate 
analysis revealed a significant correlation 
between the increasing levels of α-










Mutations in LRRK2 and α-synuclein proteins are known to be responsible 
for autosomal dominant forms of PD [2]. Due to the growing interest in the 
potential interaction of these proteins in the pathogenesis of PD [10,18], we 
investigated such an interaction using a variety of techniques. Co-
immunoprecipitation showed that endogenous LRRK2 and α-synuclein interact in 
cells, mouse and human brain tissue. We also confirmed this interaction in over-
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expression studies in HEK-293 cells, where the use of several LRRK2 construct 
revealed that the N terminal of LRRK2 is requires for the interaction with α-
synuclein. 
In this model, we found that the G2019S mutation did not alter the ability of 
LRRK2 to interact with α-synuclein. Nevertheless, we cannot exclude that the 
interaction with G2019S is not potentiated due to the over-expression of the 
protein in HEK cells. The G2019S mutation is located in the kinase domain of 
LRRK2, and shows an enhanced kinase activity compared to WT LRRK2 [19]. Our 
data indicate that the kinase domain and therefore the phosphorylation capacity of 
LRRK2 do not play a large role in its interaction with α-synuclein. This is consistent 
with recent evidence showing that the levels of rather than mutations in LRRK2 
are related to the deposition of neuropathology [20]. Overall, these results 
unequivocally demonstrate, for the first time, a definite interaction between 
endogenous LRRK2 and α-synuclein, a finding that had only been detected under 
pathological and oxidative stress conditions [11]. 
In human PD brains, we show co-localization of LRRK2 and α-synuclein as 
well as S129 phosphorylated α-synuclein in LBs and also co-localization in 
neurons that have not formed LBs in LB producing regions. We have also 
replicated this co-localization of LRRK2 and α-synuclein in an established cell 
model for α-synuclein inclusion formation. Of interest, our quantitation in the PD 
cases showed that LRRK2 co-localized in more cortical compared with brainstem 
LBs. According to Braak PD staging [12], cortical LBs develop later in PD, further 
suggesting an early association between LRRK2 and α-synuclein in LB formation. 
In these neurons, S129 phosphorylated α-synuclein fibrils often appeared to 
radiate from more centralized LRRK2 within LBs. Overall, our results suggest that 
the interaction between LRRK2 and α-synuclein or S129 phosphorylated α-
synuclein is enhanced prior to and during the formation of α-synuclein aggregation 
and fibrilization. These data are also consistent with other studies in brain tissue 
showing the co-localization of LRRK2 in α-synuclein-immunoreactive LBs [21–23], 
although questions regarding the specificity of the different LRRK2 antibodies 
used have been raised [24, 25]. While variance in the numbers of LBs co-
localizing LRRK2 may be due to the age of the LBs assessed (see above) and 
account for some of the differences described in the literature, we are certain of 
the specificity of the antibodies used in the current study, as a number of 
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specificity experiments confirmed that the protein we localized to early forming LBs 
was LRRK2. 
To test this association further, we knocked down LRRK2 in a cell model of 
α-synuclein inclusion formation and found that reduced LRRK2 expression altered 
α-synuclein inclusions, resulting in an increased number of smaller inclusions per 
cell. In this model, α-synuclein is co-expressed and co-aggregates with synphilin-
1, as observed in LBs [26, 27]. Synphilin-1 recruits and binds α-synuclein leading 
to inclusion formation [26], and synphilin-1 and 14-3-3 proteins accumulate with 
mutant α-synuclein in A53T transgenic mice [28]. While there is little indication that 
synphilin-1 closely associates with LRRK2, 14-3-3 proteins are not only known to 
interact with and stabilize phosphorylated LRRK2 [29] but also have a preference 
for binding S129 phosphorylated α-synuclein [30] and accumulate in LBs [31]. 14-
3-3 proteins and α-synuclein have opposing effects on regulating the activity of 
many enzymes [31], and such regulation may occur within a complex associated 
with LRRK2. The microtubule binding protein Tau phosphorylation complex has 
been shown to require both 14-3-3 and α-synuclein [32, 33], and it is of interest 
that over-expression of Tau has a similar effect on the formation of α-synuclein 
inclusions in this cellular model [34] to the knockdown of LRRK2 (present study), 
as well as sequestering phosphorylated Tau into the inclusions [34]. Either 
reducing the amount of unbound α-synuclein by enhanced recruitment into the tau 
phosphorylation complex and/or increased tau partnering of 14-3-3 to shift its 
binding from and decrease the phosphorylation and activity of LRRK2, would 
seem to produce similar effects on the formation of α-synuclein inclusions in this 
cellular model of inclusion formation. In mouse models, LRRK2 over-expression 
enhances the progression of α-synuclein-mediated neuropathological changes, 
and LRRK2 deletion delays the progression of pathology [20]. All of these data are 
consistent with an interaction between LRRK2 and α-synuclein in patients with PD. 
This is the first study showing correlations between the relative protein 
levels of LRRK2 and phosphorylated and total α-synuclein in PD human brain 
tissue extracts, but not in controls. A small increase in the levels of LRRK2 in the 
brain tissue from PD patients directly correlated with much larger regional 
increases in α-synuclein levels, and more strikingly with a widespread α-synuclein 
S129 phosphorylation. In cell models, an increase in LRRK2 expression 
significantly increases α-synuclein mRNA [35], and elevated α-synuclein mRNA 
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levels are co-regulated with increased LRRK2 transcription [36]. The positive 
feedback in turn activates the ERK signaling pathway leading to phosphorylation 
of α-synuclein [35]. It is of interest that in long duration PD cases, the gene 
expression levels of both LRRK2 [37] and α-synuclein [38] are decreased in 
multiple brain regions forming LBs. This is possibly as a self-protective mechanism 
to the high levels of these proteins that accumulate within neurons in these 
regions, and suggests that deficits in protein degradation mechanisms play a 
significant role in the progression of pathology overtime. Beyond the endogenous 
interaction of LRRK2 and α-synuclein that we have shown in this study, we are still 
not able to determine whether the nature of LRRK2 interaction with α-synuclein is 
a direct protein-protein binding or an indirect binding within a protein complex. As it 
has been extensively suggested, LRRK2 interacts with other proteins also 
implicated in PD to form protein complexes [10, 18, 20, 29, 37, 39]. While a fine 
analysis of the molecular determinants of the interaction between LRRK2 and α-
synuclein is still required, our study has unequivocally established that there is an 
interaction between LRRK2 and α-synuclein, and that this interaction appears to 
be enhanced in patients with PD and in cell models of α-synuclein inclusion 
formation. Importantly, we also provide evidence showing that the levels of LRRK2 
impact on α-synuclein pathology, consistent with studies in animal models of PD 
[20]. Ultimately, our work paves the way for the understanding of the molecular 
interplay between two central players in PD. 
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Chapter 4. LRRK2 promotes Tau accumulation, aggregation and 
release 
 
4.1 Introduction and main goals 
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are known as 
the most frequent cause of autosomal dominant Parkinson’s disease (PD). The 
importance of LRRK2 in PD was further substantiated by the discovery that 
several mutations linked to familial forms of the disease can also be associated 
with sporadic cases [1,2,3,4]. LRRK2 is a large protein of 2527 amino acids, 
composed of several defined domains. The two enzymatic domains, the GTPase 
(ROC/COR) and the kinase (MAPKKK), lie at the centre of the protein, but the 
latter is responsible for the classification of LRRK2 as a protein kinase [5,6]. 
Although PD-associated mutations are found dispersed throughout the protein, the 
most frequent G2019S mutation is present in the kinase domain. This mutation 
has been consistently associated with a pathological gain-of-function [7,8].  
LRRK2-associated familial PD cases are indistinguishable from sporadic 
cases, with late onset of the disease and the presence of widespread protein 
aggregates, enriched in proteins like α-synuclein or Tau, in the remaining neurons, 
particularly [9]. LRRK2 function has been implicated in a number of cellular 
processes, including synaptic vesicle recycling, neurite branching, mitochondrial 
homeostasis, protein synthesis and protein clearance/degradation. However, the 
precise physiological role of LRRK2 in regulating these processes is still unclear 
[5,10,11]. 
Tau is predominantly an axonal protein, encoded by the MAPT (microtubule-
associated protein tau) gene. Through alternative splicing, six isoforms of the 
protein can be originated from the MAPT gene (ranging from 352 to 441 amino 
acids). Tau is highly expressed in the adult central nervous system [12] and its 
main function is the stabilization of the microtubule network through the binding of 
the microtubule-binding domains in the C-terminal half of Tau to tubulin [13]. The 
interaction of Tau with microtubules is modulated by phosphorylation of specific 
epitopes, some of which have been described as pathogenic in neurodegenerative 
diseases such as Alzheimer’s disease or PD [14,15]. Both the autophagy-
lysosome pathway (ALP) and the ubiquitin-proteasome system (UPS) are 
important for Tau degradation [16,17]. Consistently, it was shown that dysfunction 
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in either of these two major protein clearance systems might initiate or facilitate the 
process of Tau accumulation and aggregation, typical in neurodegenerative 
processes [18,19,20].  
Recent in vitro studies demonstrated that LRRK2 phosphorylates tubulin-
associated, but not free Tau protein [21]. A separate study showed that LRRK2 
promotes Tau phosphorylation indirectly via GSK-3β [22]. In mice, expression of 
transgenic LRRK2 in a model of tauopathy increases the aggregation of insoluble 
Tau and its phosphorylation in different residues (T149, T153, T205) [23]. Thus, 
our goal was to further detail the interaction between LRRK2 and Tau to provide 
novel insight into the role of these proteins in PD.  
 Here, we show an interaction between LRRK2 and Tau. We found that 
LRRK2 expression resulted in increased intracellular Tau levels, promoted the 
accumulation of oligomeric Tau, and enhanced Tau secretion. These effects 
appeared independently from LRRK2 kinase activity. Moreover, we show that Tau 
accumulation occurs due to LRRK2-mediated impairment of the proteasome, but 
not of the autophagy pathway. In total, our data suggest that LRRK2 increases the 
levels of Tau protein via proteasomal inhibition.  
 
4.2 Materials and methods 
Plasmids 
Wild type human LRRK2 (LRRK2 WT) was cloned into a pLenti6/V5-Dest 
vector by gateway recombination. LRRK2 triple kinase-dead (K1906A, D1994N, 
D2017A) and G2019S mutations were introduced by site-direct mutagenesis 
(Agilent Technology, CA, USA). The cDNA according to the longest human Tau 
isoform (4R2N) was cloned into the pcDNA3.1 vector (Invitrogen, Darmstadt, 
Germany). For the constructs used in BiFC interactions, Venus cDNA was divided 
asymmetrically into a larger 5’-fragment, corresponding to amino acids 1-158, and 
a smaller 3’-fragment, corresponding to amino acids 159 - 239. LRRK2 cDNA was 
cloned to the 3’-end of the Venus 5’-fragment (VN-LRRK2) and Tau cDNA was 
cloned upstream of the Venus C-terminal fragment (Tau-VC) or downstream of 
Venus N-terminal fragment (VN-TAU). The GFP-Rab6b plasmid was a kind gift 
from Dr. Mika Simons, Department of Neurology, UMG, Göttingen.  
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Cell culture, transfections and inhibitors 
Human Embryonic Kidney 293 cells (HEK-293) were grown in Dulbecco’s 
modified Eagle’s medium (PAN, Aidenbach, Germany), supplemented with 10% fetal 
calf serum and 1% penicillin/streptomycin, at 37ºC in 5%CO2. The cells were 
transfected 24 hours after plating using Metafectene (Biontex Laboratories GmbH, 
Martinsried, Germany), according to the manufacturer’s instructions. 48 hours post-
transfection, the cells were harvested or treated for additional 24 hours with 5µM Z-
Leu-Leu-Leu-al (MG132) (Sigma, Hamburg, Germany), 20mM ammonium chloride 
and 100µM leupeptin (NL) (Merck, Darmstadt, Germany), and 50nM bafilomycin A1 
(Sigma, Hamburg, Germany). 
 
SDS-PAGE and Western blotting  
Cells were collected in lysis buffer (25mM Tris–HCl pH 7.6; 150mM NaCl; 
0.1% SDS; 1% NP40) supplemented with protease inhibitor cocktail (Roche, 
Mannheim, Germany), sonicated, and cleared by centrifugation for 10 minutes at 
10,000xg. Total protein concentration was determined using the Bradford assay 
(BioRad Laboratories, CA, USA). The lysates were boiled at 95ºC for 5 minutes in 
protein sample buffer (PSB, 50mM Tris–HCl pH 6.8; 2% SDS; 10% glycerol; 1% β-
mercaptoethanol; 0.02% bromophenol blue), and resolved by SDS-PAGE in a 
10% Tris-glycine gel. Proteins were transferred for 1-2 hours at 250mA to 
nitrocellulose or PVDF membranes (Immobilon-FL-Membrane, Millipore, Billerica, 
MA, USA) and blocked for 1 hour in TBS-Tween with 3% non-fat milk or BSA, 
respectively. The membranes were incubated overnight at 4°C with primary 
antibodies using the following dilutions: LRRK2 (c41-2 MJFF, Epitomics, 
Burlingame, CA, USA) 1:1000, Tau (HT7, Thermo Scientific) 1:3000, GFP (C-2, 
Santa Cruz Biotechnology, USA) 1:3000, LC3 (5F10, Nanotools, Teningen, 
Germany) 1:500, p62 (SQSTM1, Sigma, Hamburg, German) 1:1000, β-actin 
(Sigma, Hamburg, German) 1:3000. Membranes were washed with TBS-Tween 
and incubated for 1 hour at room temperature with the corresponding HRP-
labelled secondary antibodies (GE Healthcare, UK, 1:10,000). Immunoreactivity 
was visualised by chemiluminescence using an ECL detection system (Millipore, 
Billerica, MA, USA). 
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Mouse brain samples 
Brains from adult LRRK2 knockout (LRRK2 KO), transgenic LRRK2 Thy-1 
LRRK2-WT (LRRK2 Tg) and wild type (WT) mice were lysed in RIPA buffer 
(25mM Tris-HCl pH 7.6; 150mM NaCl; 0.1% SDS; 1% NP40), supplemented with 
protease inhibitor cocktail (Roche diagnostics, Mannheim, Germany) using a 
mechanic homogenizer (Precellys24, Peqlab, Erlangen, Germany). Lysates were 
cleared by centrifugation at 10,000g for 10 min at 4°C. Samples were resolved by 
SDS-PAGE and analysed as described above. 
 
Co-Immunoprecipitation (co-IP) 
For the co-IP assay, cells were collected in IP buffer (50mM Tris-HCl pH7,5; 
0.5mM EDTA; 150mM NaCl; 0.05% NP40) supplemented with protease inhibitor 
cocktail (Roche, Mannheim, Germany) and sonicated. In each IP sample, 
approximately 1mg of total protein lysate was pre-cleared by incubation with 20µl 
of protein G beads (Invitrogen, Barcelona, Spain) for 30 minutes at 4°C in rotation. 
Pre-cleared samples were incubated with 2µg of the IP antibody, LRRK2 (c41-2 
MJFF), overnight at 4°C in rotation, mixed with 40µl of protein G beads, and 
incubated for additional 3 hours. Beads were washed 5 times with IP buffer, re-
suspended in 20µl of PSB and boiled at 95ºC for 5 minutes. The supernatants 
were loaded onto a 10% SDS gel, and the Western Blotting was performed as 
described above.  
 
Size-exclusion chromatography (SEC), dot blot and filter trap assays 
HEK-293 cells were collected 48 hours after transfection in a phosphate 
buffer (1X PBS with 0,5% TritonX-100) freshly supplemented with protease 
inhibitor cocktail (Roche, Mannheim, Germany) and centrifuged for 10 minutes at 
10,000xg. 2-3mg of total protein in a maximum volume of 500ul was filtered using 
a 0,45µm Spin-X centrifuge filter (Sigma, Hamburg, Germany) before loading onto 
a Superose 6 (Superose 6 10/300GL. GE Healthcare Life Science, Sweden) 
column and subsequent high-performance liquid chromatography (HPLC) (Äkta 
Purifier 10, GE Healthcare Life Science, Sweden) in 50mM ammonium acetate pH 
7.4 buffer with a flow rate of 0.5 ml/min. The collected HPLC fractions of 500ul 
were boiled at 95ºC for 10 minutes and centrifuged at 10,000xg for 5 minutes. For 
the dot blot assay, 150ul of the supernatant were loaded on a nitrocellulose 
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membrane, and for the filter trap assay, 350µl were loaded on a cellulose acetate 
membrane, previously soaked in PBS buffer, using a dot blot vacuum system. 
Membranes were further processed as described under Western blotting except 
that all steps were performed in PBS instead of TBS.  
 
Measurement of 26S proteasome catalytic activity 
The chymotrypsin-like activity of the 26S proteasome was determined using 
N-Succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC, Enzo, 
Life-Sciences) as substrate. 48 hours after transfection, cells were collected in 
lysis buffer (50mM Tris, pH 7.5, 250mM Sucrose, 5mM MgCl2, 1mMDTT, 0.5mM 
EDTA, 0.025% Digitonin, protease inhibitors, 2mM ATP) and centrifuged for 15 
minutes at 20,000g for removal of cell debris. Each reaction was performed with 
12µg of total protein lysates in a final volume of 100ul in a 96-well plate and 
initiated by the addition of reaction buffer (50mM Tris (pH 7.5), 40mM KCl2, 5mM 
MgCl2, 1mM DTT, 0.5mM ATP, 100µM Suc-LLVY-AMC). The fluorescence of 
AMC (380nm excitation and 460nm emission) was monitored in a microplate 
fluorometer (Infinite M1000, Tecan) at 37ºC for 1 hour, and values were calibrated 
to standard curves of AMC (0 - 5µM). Inhibition of the proteasome was controlled 
by the incubation of samples with 20µM MG132 (Sigma, Hamburg, Germany) prior 
to the measurements. 
 
Secretion Assays 
24 hours after transfection, HEK-293 cells were washed with PBS, and the 
culture medium was replaced by serum-free medium. 48 hours later, 2ml of the 
serum-free medium were collected and cleared by sequential centrifugation for 5 
minutes at 300g and 10 minutes at 10,000g. The samples were boiled for 10 
minutes at 95 °C and loaded on a nitrocellulose membrane using a dot blot 
vacuum system. Membranes were further processed as described under Western 
blotting using PBS instead of TBS in all steps. 100µl of cleared medium were used 
to determine the cytotoxicity with the Lactate Dehydrogenase (LDH) assay 
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Immunohistochemistry and microscopy 
48 hours after transfection, cells were washed with PBS and fixed with 
PBS/4% paraformaldehyde. The cells were permeabilized with PBS/0.1% Triton X-
100, blocked for 1 hour with 1.5% BSA and incubated overnight with the primary 
antibody for LRRK2  (c41-2 MJFF) 1:1000. After 3 washes with PBS, the 
secondary antibody anti-rabbit IgG conjugated to Alexa Fluor 568 (Molecular 
Probes, Oregon, USA) 1:1000 was added for 1 hour at room temperature.  Cell 
nuclei were stained with Hoechst dye (Hoechst 33258, Molecular Probes, OR, 
USA). Fluorescent images were captured either using a Leica Microsystems 
microscope (Leica DMI 6000B, Wetzlar, Germany) or an automatic microscope 
Olympus (IX81-ZDC, Hamburg, Germany). Venus fluorescence was quantified 
from 16 fields of cell images automatically collected with the Olympus microscope 
and analysed by the ScanR software. 
 
4.3 Results 
4.3.1 Tau levels are decreased in LRRK2-KO mice  
To investigate the interplay between LRRK2 and Tau, we first compared the 
levels of endogenous Tau protein in transgenic mice expressing human LRRK2 
under the Thy1 promoter (LRRK2-Tg), LRRK2 knockout mice (LRRK2-KO) and 
wild type littermate control animals (WT). Interestingly, we found that while the 
levels of Tau were identical in wild type and LRRK2 transgenic animals, they were 
drastically reduced in the LRRK2-KO mice (Figure 1).  
 
 
Figure 1. Tau levels are decreased in 
LRRK2-KO mice.  
Immunoblot analysis of total brain lysates 
from LRRK2-KO mice, LRRK2 WT 
transgenic mice and littermate control 
mice, showing that the knockout of LRRK2 
is accompanied by a decrease of the 
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4.3.2 LRRK2 physically interacts with Tau 
To investigate the interaction between Tau and LRRK2, we performed co- 
immunoprecipitation (co-IP) assays. We co-expressed LRRK2 and Tau in HEK-
293 cells, and then immunoprecipitated LRRK2 with a specific LRRK2 antibody. 
The co- IP of Tau was verified with a specific human Tau antibody (Figure 2A).  
Next, to investigate the subcellular localization of the interaction between 
the two proteins, we took advantage of the bimolecular fluorescence 
complementation (BiFC) assay, which enables the direct visualization of protein-
protein interactions in living cells [24]. We designed BIFC constructs, combining an 
N-terminal fragment of Venus protein fused to the N-terminus of LRRK2 (VN-
LRRK2) and the C-terminal fragment of Venus fused to the C-terminus of Tau 
(Tau-VC). Upon co-transfection of the two constructs in HEK-293 cells, we 
observed widespread fluorescence signal inside the cell, confirming the interaction 
between LRRK2 and Tau, as expected, in the cytoplasm, and no fluorescence in 
the isolated constructs (Figure 2B). The expression of LRRK2 and Tau was 
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Figure 2. LRRK2 physically 
interacts with Tau.  
(A) Human LRRK2 and human 
Tau were expressed in HEK-293 
cells. Following the 
immunoprecipitation (IP) of 
LRRK2, the co-IP with Tau is 
demonstrated with a Tau-specific 
antibody. (B) Schematic 
representation of the BiFC 
constructs, VN-LRRK2 and Tau-
VC. (C) and (D) The co-
expression of BiFC constructs in 
HEK-293 cells results in the 
formation of reconstituted Venus 
fluorescent protein in the cells 
indicating that LRRK2 and Tau 
can interact. The immunoblots and 
fluorescence images are 
representative of more than 3 
independent experiments. Scale 
bar 20µm.	
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4.3.3 Increased levels of Tau depend on LRRK2 expression but not on its 
kinase activity 
Next, we investigated whether LRRK2 affected the levels of Tau in human cells. 
Thus, we expressed Tau in HEK-293 cells alone or together with LRRK2, and the 
levels of both proteins were assessed at three different time points after 
transfection. Expression of Tau and LRRK2 was detected already 12 hours after 
transfection, and the levels of both proteins continually increased over time up to 
48 hours. At 24 hours and 48 hours post-transfection Tau levels were significantly 
increased when co- expressed with LRRK2 (Figure 3A).  
We next asked whether this effect could be due to the kinase activity of LRRK2. 
Thus, we compared the levels of Tau when co-expressed with three different 
forms of LRRK2: wild type (WT), kinase-dead mutant (KD) or G2019S mutant 
(GS). We found that the Tau levels equally increased in the presence of any of the 
three forms of LRRK2 (Figure 3B). To verify whether the effect of LRRK2 on Tau 
levels was specific, or whether it was simply due to the clogging of degradation 
pathways due to the expression of a large protein such as LRRK2, we co-
expressed Tau with ATP13A2, another large protein (1180 amino acids) 
associated with PD [25]. In this case, no increase in Tau levels was observed 
(Figure 3C).  
In order to determine whether LRRK2 also affected the levels of oligomeric Tau, 
we used the BiFC assay, in living cells. The Tau BiFC constructs (VN-Tau and 
Tau-VC) were expressed together with the three forms of LRRK2 (WT, KD, and 
GS) or with a control plasmid in HEK-293 cells. The various forms of LRRK2 
promoted an identical increase in Tau BiFC signal when controlled for comparable 
levels of LRRK2 protein expression (Fig. 3D,E), confirming that the kinase activity 
of LRRK2 is not required for the increase of monomeric and oligomeric Tau levels.  
Next, to assess whether the elevated levels of Tau protein in the presence 
of LRRK2 were due to increased tau gene transcription or tau mRNA stabilization, 
we quantified tau mRNA levels by real-time PCR. Tau was expressed in HEK-293 









































Figure 3. Increased levels of Tau depend on LRRK2 expression but not on its 
kinase activity.  
(A) The expression of Tau±LRRK2 in HEK-293 cells over time shows significant 
increasing amounts of Tau protein were further augmented in the presence of LRRK2 
after 24 hours. *p≤0.05. (B) The expression of Tau alone or together with the three forms 
of LRRK2, wild type (WT], kinase-dead (KD) and G2019S (GS) for 48 hours clearly shows 
that LRRK2 promoted an increase in the levels of Tau independent from its kinase activity 
(n=3]. (C) The expression of Tau alone and together with LRRK2 or ATP13A2 shows an 
increased Tau accumulation in the presence of LRRK2, but not of ATP13A2. (D) Tau 
BiFC constructs (VN-Tau and Tau-VC) were expressed in HEK-293 cells together with an 
empty plasmid (pcDNA3.1) or with LRRK2 wild type (WT], kinase-dead (KD) or G2019S 
(GS]. Fluorescence microscopy confirms the formation of increased levels of Tau 
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quantification of the mean fluorescence intensity (±SD) in each group from three 
independent transfections, **p≤0.01. (F) Real time PCR with samples from the same 
transfections as in (B), demonstrating that Tau mRNA levels (±SD) are not altered in the 
presence of any of the three LRRK2 forms (N≥3].  
 
the respective control. After normalization to β-actin mRNA, we found no 
significant differences in the levels of tau mRNA in the presence of any of the 
LRRK2 forms (Figure 3F). Taken together, our data demonstrate that LRRK2 
promotes an increase in Tau protein levels without affecting Tau mRNA levels. 
 
4.3.4 LRRK2 promotes the accumulation of high-molecular weight Tau 
species 
Tau oligomerization and aggregation, with the formation of high-molecular 
weight species, is strongly associated with AD and PD [16-18]. 
To further explore whether the LRRK2-mediated increase in Tau levels 
affected the biochemical state of Tau, we performed size-exclusion 
chromatography (SEC) and analysed the various fractions using a dot blot assay. 
First, GFP-tagged Tau was co-expressed with LRRK2 in HEK-293 cells, and the 
lysates were separated by SEC. The chromatograms show that, in the presence of 
LRRK2, additional GFP signal peaks appeared in fractions corresponding to Tau 
species with higher molecular weight. The shift in Tau signal, towards high-
molecular weight species, was confirmed in a dot blot assay, upon immunoblotting 











Figure 4. LRRK2 promotes the accumulation of high-molecular weight species of 
GFP-Tau.  
Lysates from HEK-293 cells expressing GFP-Tau, or GFP-Tau together with LRRK2 were 
separated by SEC/ HPLC. The chromatograms show the signal of total protein (black 
GFP-Tau + pcDNA 3.1 
GFP (Tau)!
Total protein!
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trace) and the signal of GFP (red trace) correspondent to GFP-Tau protein. The presence 
of LRRK2 promotes additional GFP signal peaks in fractions corresponding to higher 
molecular weight species. This shift was confirmed in a dot blot with the collected SEC-
HPLC fractions onto a nitrocellulose membrane followed by staining with a Tau-specific 
antibody. 
 
To ensure the effects observed were not due to the GFP tag, we also used 
untagged Tau.  
Likewise, to rule out that the biochemical differences were simply explained 
due to the increased Tau levels in the presence of LRRK2, we performed an 
additional experiment where we transfected cells with twice the amount of Tau 
cDNA. Indeed, Western blot analysis of the samples with a Tau-specific antibody 
confirmed that the Tau levels were increased in the presence of LRRK2, and that 
the levels were even higher upon transfection with twice the amount of Tau 
plasmid DNA (Figure 5A). Analysis of these samples by SEC, and subsequent dot 
blot assays, revealed that, although the double amount of DNA during transfection 
lead to an increase in total Tau protein levels, the presence of LRRK2 promoted a 













Figure 5. LRRK2 promotes the accumulation of high-molecular weight Tau species  
(A) Lysates from HEK-293 cells expressing Tau, twice the amount of Tau (2X) or Tau 
together with LRRK2 were analysed by immunobloting using the respective specific 
antibodies highlights the significant effect of LRRK2 in increasing the levels of Tau is 
comparable with the expression of twice the amount of Tau. *p≤0.05. (B) The same 
samples were separated by SEC/HPLC and the distribution of total Tau in the collected 
fractions was determined by dot blot with a Tau-specific antibody. The presence of LRRK2 
clearly induces a shift of Tau signal to the three first fractions from the left, corresponding 
to higher molecular weight species. (C) The same fractions were separated by filter trap 
using a cellulose acetate membrane and detected with a Tau-specific antibody. In the 
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presence of LRRK2, larger Tau species were trapped and detected in the fractions 
corresponding to high-molecular weight species, which was not observed by simple 
overexpression of Tau in the control sample (2x Tau) indicating that LRRK2 promotes the 
formation of larger Tau species or Tau aggregates. The Western blots and dot blots are 
representative of N≥3. 
 
 
We also performed filter trap assays, using a low-protein binding cellulose 
acetate membrane, in order to confirm the accumulation of large Tau species. As 
expected, Tau reactivity was detected for the first three fractions corresponding to 
the higher molecular weight species, further confirming the accumulation of 
aggregated Tau in the presence of LRRK2 (Figure 5C). 
 
4.3.5 LRRK2 impairs proteasomal protein degradation independently of its 
kinase activity 
LRRK2 plays a role in proteostasis through modulation of protein quality 
control systems, such as the ubiquitin-proteasome system (UPS) and the 
autophagy-lysosome pathway (ALP) [11, 25, 26]. Importantly, these quality control 
mechanisms are indispensable for the clearance and degradation of Tau protein, 
thereby avoiding the accumulation of Tau and subsequent formation of high-
molecular weight aggregated species that are characteristic in neurodegenerative 
processes [16-20]. In order to confirm the effect of LRRK2 on the UPS, we co-
expressed the different LRRK2 forms (WT, KD, and GS) together with the UPS 
reporter GFPu, an unstable version of GFP that is degraded via the proteasome 
[27]. The presence of any of the three forms of LRRK2 clearly promoted an 
increase in the GFPu levels, visible by microscopic analysis (Figure 6A) and by 
immunoblot analysis (Figure 6B). The increased levels of GFPu reflect the 
accumulation of this protein possibly due to an impairment of proteasomal 
degradation promoted by LRRK2, in a kinase-independent manner, since no 
differences were observed in the presence of either KD or GS mutants.  
We also compared the effect of LRRK2 with that of MG132, a known 
proteasome inhibitor and found that, although both caused an increase in GFPu 
accumulation, the inhibitor promoted a strong effect (~4.5 fold over the control) 
that was not further potentiated in the presence of LRRK2 (Figure 6C).  
Next, we investigated whether LRRK2 impairs the UPS, by affecting the 
proteolytic activity of the proteasome. The chymotrypsin-like activity of eukaryotic 
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proteasomes is often considered the most important in protein degradation [28]. 
Thus, we performed an in vitro assay to measure the chymotrypsin-like catalytic 
activity of the 26S proteasome, in lysates from cells expressing LRRK2, using 
Suc-LLVY-AMC as substrate. Interestingly, we did not observe differences in the 

























Figure 6. LRRK2 impairs proteasomal protein degradation independently of its 
kinase activity. 
(A)The ubiquitin-proteasome reporter GFPu and LRRK2 wild type (WT), kinase dead 
(KD)or G2019S (GS) were expressed in HEK-293 cells. Fluorescence microscopy reveals 
the expression of GFPu and enhanced levels of GFPu in the presence of LRRK2 protein. 
Scale bar 20µm. (B) Western Blot performed with the same transfections demonstrating 
the accumulation of GFPu in the presence of the three forms of LRRK2 using LRRK2 and 
GFP-specific antibodies. (C) Proteasomal inhibition of GFPu-expressing HEK-293 cells 
using 5µM MG132 promotes a more pronounced accumulation of GFPu than the co-
expression of LRRK2. Both together, LRRK2 co-expression and treatment with 5 µM 
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pcDNA3.1 or LRRK2 were subjected to an in vitro assay to measure the catalytic activity 
of the chymotrypsin-like proteasome active site. The fluorescence (380nm excitation and 
460nm emission) of the samples (±SD) calibrated to a standard curve with AMC 
concentrations from 0 to 5 µM shows, that LRRK2 does not alter the activity of this active 
site. Incubation with the MG132 proteasome inhibitor was used as control and significantly 
decreased the proteasomal activity. **p≤0.01. The Western blots, fluorescence images 
and in vitro assays are representative of N≥3 experiments. 
 
 
4.3.6 LRRK2 impairs the proteasomal degradation of Tau but does not 
interfere with the autophagy pathway 
In order to investigate the effect of LRRK2 on Tau clearance in the cell, we 
started by using a similar approach to that described above for GFPu.  
We observed that blockade of the proteasome with MG132 caused a strong 
accumulation (2,5-fold over the control) of Tau protein. LRRK2 also promoted a 
pronounced increase in Tau levels, although to a smaller extent (~1,5-fold over the 
control). Our results confirm that the UPS is an important mechanism for Tau 
clearance, and that LRRK2 interferes with Tau proteasomal degradation, 
promoting its accumulation (Figure 7A). Next, we asked whether the effect of 
LRRK2 on Tau levels was solely due to proteasomal inhibition or whether it was 
also due to an interference with autophagy. To tackle this, we used different 
autophagy inhibitors, such as ammonium chloride/leupeptin or bafilomycin, to treat 
cells expressing Tau alone or in combination with LRRK2. Autophagy inhibition 
was confirmed by the accumulation of the autophagy markers LC3 and p62 
(Figure 7B). The accumulation of Tau, when co-expressed with LRRK2, was not 
further potentiated by simultaneous treatment with the autophagy inhibitors, 
suggesting that the increase in Tau levels was not mediated through LRRK2 
interference with the autophagy-lysosome pathway (Figure 7B). To further confirm 
that LRRK2 had no impact on autophagy, we assessed the levels of GFP-Rab6b, 
a protein known to be preferentially degraded by autophagy, in the presence of 
LRRK2. As predicted, we observed no differences in the levels of GFP-Rab6b, 
confirming that LRRK2 does not interfere with the autophagy-lysosome system 
(Figure 7C). 
 
4.3.7 LRRK2 promotes the cellular release of Tau  
In addition to the intracellular accumulation of aggregated Tau, the 
release/secretion of the protein to the extracellular space and subsequent uptake 
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by neighbouring cells is thought to contribute to the neurodegenerative process 
[29]. In order to determine if LRRK2 affected Tau release from cells, we analysed 




Figure 7. LRRK2 impairs proteasomal degradation of Tau but does not interfere 
with the autophagy pathway.  
(A) Immunoblots showing that Tau levels were significantly increased in HEK-293 cells 
expressing the protein and being treated with 5µM of MG132 (**p≤0.01) and also when 
co-expressed with LRRK2 (*p≤0.059). (B) HEK-293 cells expressing Tau±LRRK2 
remained untreated (Ctrl) or were treated with the autophagy inhibitors 20mM of 
ammonium chloride / 100µM leupeptin (NL) or 50nM of bafilomycin (Baf). Immunoblot 
showing the increased levels of LC3I/II and p62 proteins verified the efficient inhibition of 
autophagy. The significant (**p≤0.01) accumulation of Tau when co-expressed with 
LRRK2, was not further potentiated by simultaneous treatment with the autophagy 
inhibitors. (C) Lysates from HEK-293 cells expressing LRRK2 together with GFP-Rab6b, a 
specific target of autosomal degradation, show that LRRK2 did not alter the levels of 
Rab6b. The Western blots are representative of N=3. 
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To detect the levels of Tau, the medium was loaded onto a nitrocellulose 
membrane using a dot blot system, and Tau was detected after immunoblotting 
with an anti-Tau antibody. We found that, in the presence of LRRK2, the levels of 
Tau in the medium increased ~1.6-fold over the control (Figure 8A). The 
expression of LRRK2 and Tau in HEK-293 cells was confirmed by SDS-PAGE and 
immunoblot analyses with specific antibodies for each protein (Figure 8B). The 
enhanced release of Tau could be a consequence of increased intracellular Tau 
levels due to co-expression of LRRK2, a LRRK2-mediated increase in Tau 
secretion or simple to increased toxicity and cell death in the presence of LRRK2. 
Thus, to assess whether the release of Tau was due to either the presence 
of LRRK2 or simply due to increased cytotoxicity and consequent membrane 
leakage, we performed LDH assays to measure the activity of LDH in the medium. 
We observed that the co-expression of Tau and LRRK2 did not increase the basal 
levels of toxicity induced by Tau alone (Figure 8C). This confirmed that the 













Figure 8. LRRK2 promotes the cellular release of Tau.  
(A) 24 hours after transfection, HEK-293 cells expressing Tau and LRRK2 were cultured 
in serum-free media for additional 48 hours. Cell culture media were cleared by sequential 
centrifugation at 300g and 10,000g, probed on a dot blot nitrocellulose membrane and 
stained with specific antibodies. In the presence of LRRK2, the amount of Tau secreted 
into the medium was significantly enhanced  (*p≤0.05). (B) The expression of Tau and 
LRRK2 was confirmed by SDS-PAGE using the cell lysates. (C) The graph represents the 
toxicity levels in the respective samples quantified by the Lactate Dehydrogenase (LDH) 
assay showing that enhanced release of Tau into the medium is not due to enhanced cell 
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LRRK2 mutations are associated with both, familial and sporadic cases of 
PD and display clinical features undistinguishable from those in idiopathic PD. This 
suggests a high degree of similarity in the underlying molecular mechanisms and 
pathways in genetic and sporadic forms of the disease. Thus, investigating the 
interplay between LRRK2 and other PD-associated proteins is essential for our 
understanding of the molecular basis of PD [30-33]. Although the interplay 
between LRRK2 and Tau is attractive given the relevance of both proteins in PD, it 
is presently unclear whether this has implications in the pathophysiology of 
disease. Contradictory results about the role of LRRK2 in phosphorylating Tau [34, 
35] suggest the interplay between the two proteins is complex. One hypothesis is 
that LRRK2 may influence cytoskeleton dynamics, through direct or indirect 
interactions with microtubule-related proteins like α-β-tubulin, ezrin/radixin/moesin 
or Tau [21, 22, 35-40].  
 The interaction of LRRK2 with Tau was previously observed using 
recombinant proteins in an in vitro assay [21]. Here we demonstrate that this 
interaction occurs lso in the contex og a living cellular environment. Moreover, we 
found that increased LRRK2 expression is paralleled by an increase in total Tau 
levels. This effect is also observed in the presence of a kinase-dead mutant or of 
the over-active mutant G2019S, suggesting the effect is independent of the kinase 
activity of LRRK2 on Tau. Interestingly, we found a drastic reduction in Tau levels 
in LRRK2-KO mouse compared to both human WT LRRK2 transgenic mice and 
littermate controls. This result might reflect a functional difference between the 
effect of LRRK2 on human Tau when compared with mouse Tau, and should be 
further investigated as it may impact on findings observed in LRRK2 and Tau 
animal models. The intracellular accumulation of Tau results in increased 
phosphorylation and aggregation of the protein in the brains of AD and PD patients 
[29, 41-43]. This abnormal Tau accumulation was speculated to occur due to 
impairment or age-dependent decline in the activity of the two major protein 
clearance systems - autophagy and the proteasome [16, 17, 44, 45]. Again, our 
data point to a kinase-independent role of LRRK2 on Tau accumulation by 
specifically impairing the proteasome degradation of Tau, promoting its 
cytoplasmic oligomerization and the accumulation of HMW-Tau species. The 
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relation between LRRK2 and the protein quality control mechanisms has been 
explored in previous studies. Fibroblasts from patients with different LRRK2 
mutations were found to exhibit alterations in autophagy/lysosome markers [46]. In 
addition, over-expression of the G2019S LRRK2 mutant, but not WT LRRK2, 
results in increased number of autophagic vacuoles in SH-SY5Y cells [47]. LRRK2 
has also been reported to impair the proteasome, resulting in accumulation of 
several substrate proteins like ubiquitin and α-synuclein [11]. Thus, our data are 
consistent with these findings, and specifically establish a connection between 
LRRK2-mediated impairment of the proteasome and Tau accumulation. Future 
studies will be required to explore the specific nature of the Tau accumulations, 
their phosphorylation status, and the occurrence of additional post-translational 
modifications such as ubiquitination.  
 Previously, the G2019S LRRK2 mutant was also described to enhance the 
aggregate formation and phosphorylation of α-synuclein, and to contribute to α-
synuclein release into the extracellular medium [48]. Tau release via membrane 
vesicles was demonstrated upon its over-expression in HEK-293 cells [49]. Now, 
we report for the first time that Tau release is increased upon co-expression 
together with LRRK2, conceivably through LRRK2-mediated mechanisms or 
simply promoted by increased intracellular Tau levels, and that this is not due to 
increased toxicity. These novel findings shed a new light into the molecular 
mechanisms underlying the propagation of Tau between cells [50]. We speculate 
that the HMW species formed in the presence of elevated levels of LRRK2 could 
be released by cells and later on be uptaken by neighbouring cells, spreading Tau 
pathology (Figure 9). Given that LRRK2 can also be secreted, since it was found 
in neural exosomes where it interacts with several proteins [51], is possible to 
speculate that Tau release could occur in a complex together with LRRK2 and, 
eventually, with other proteins. 
Fibrillar Tau species are thought to be responsible for the impairment of the 
proteasome degradation capacity, which occurs in the brains of AD patients [16, 
41]. Therefore, our findings implicate LRRK2 in the proteasomal degradation of 
Tau in two manners: (i) it may prevent Tau-proteasomal degradation by forming a 
complex with LRRK2, Tau and eventually other proteins, or (ii) it may cause an 
indirect effect on the proteasome by promoting the accumulation of HMW-Tau 
species, which by themselves compromise proteasomal function, resulting in a 
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positive feedback loop of proteasome impairment that will be detrimental for cells 
(Figure 9). A direct impairment of the proteasome does not necessarily imply 
reduced proteolytic activity but may involve physical occupation of the proteasome 
by a large protein such as LRRK2 [52]. Although we speculate that LRRK2 causes 
the accumulation of HMW-Tau species by proteasomal inhibition, it is conceivable 
that LRRK2 directly interacts with Tau and thereby prevents its degradation.  
Altogether, our data demonstrate an interaction between LRRK2 and Tau, 
and indicate that LRRK2 increases the intracellular levels of Tau probably by 
impairing its proteasomal degradation, one of the most important systems for Tau 
clearance in the cell. This accumulation might lead to formation of HMW Tau 
species and also influence the levels of Tau secretion. These results place LRRK2 
as a central player involved in the early steps of Tau accumulation and spreading, 
suggesting it may constitute an important target for the design of novel therapeutic 









Figure 9. Proposed model for the effect of LRRK2 on Tau accumulation and release.  
LRRK2 and Tau are two proteins usually degraded by the proteasome. The increase of 
LRRK2 intracellular levels impairs Tau’s proteasomal degradation and leading to its 
accumulation. The intracellular accumulated Tau leads to the formation of high-molecular 
weight Tau species and consequently to Tau fibrils, that by themselves impair the normal 
proteasome function. Tau is released to the intercellular medium, possibly in different 
molecular weight species, and in particular the fibrils might be uptaken by the neighbor 
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Chapter 5. LRRK2 interactors and their biological significance 
 
5.1 Introduction and main goals 
Mutations in LRRK2 contribute to the pathogenesis of PD and the most 
frequent cause of inherited forms of the disease. Importantly, these mutations are 
also a risk factor for sporadic cases [1,2]. 
One of the greatest challenges in the LRRK2 field is to better understand the 
function of this complex protein and its dysfunction in the context of disease, thus, 
the identification of LRRK2-interacting proteins is critical.  
Several LRRK2 interactors have been identified using different models and 
different methodological approaches. For instance, LRRK2 interaction with Hsp90, 
CHIP and DVL1/2/3 proteins was confirmed in cell lines and mouse brain, by 
Yeast Two-Hybrid (YTH) and Co-Immunoprecipitation (Co-IP) assays [3-6]. The 
interaction with α-tubulin was confirmed by a Co-IP and actin cytoskeleton-related 
proteins were found to interact with LRKK2 by a QUICK screen and Co-IP assays 
in NIH3T3 cells [7, 8]. 
Here, we applied a combined method of LRRK2 immunoprecipitation from 
HEK cells, followed by a pull down assay from mouse brain lysates, with the goal 
of identifying new LRRK2-interacting proteins (Figure 1). The co-
immunoprecipitated proteins, potential LRRK2 interactors, were analysed by Mass 
Spectrometry, followed by bioinformatics analyses with specific software.  
 
5.2 Material and Methods 
Immunoprecipitation of LRRK2 and pull-down assay from all mouse brain 
lysate 
 Human embryonic kidney 293 cells (HEK-293) were cultured in DMEM 
medium (Invitrogen, Barcelona, Spain) supplemented with 10 % fetal bovine 
serum and 1% penicillin–streptomycin in 5% CO2 at 37°C. Cells were transfected 
with Myc-LRRK2-WT plasmid using FuGENE®6 (Roche diagnostics, Mannheim, 
Germany), according to manufacturer instructions. After 48h of transfection, cells 
were collected with IP buffer (50mM Tris-HCl pH7,5; 0,5mM EDTA; 150mM NaCl; 
0,05% NP40) supplemented with protease and phosphatase inhibitor cocktails 
(Roche, Mannheim, Germany) and sonicated 
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Figure 1. Experimental design for the identification of LRRK2 protein interactors.  
Myc tagged LRRK2-WT was expressed in HEK cells and immunoprecipitated with an 
antibody against the Myc tag. Then the beads were incubated with mouse brain lysate, 
boiled and the supernatant was loaded onto a SDS-PAGE separation gel. After 
Coomassie staining, the bands were cut from the gel and the respective proteins were 
analysed by Mass Spectrometry. The resultant list of hits was subjected to bioinformatics 
analysis. 
 
The lysate was pre-cleared by incubation with protein G beads (Invitrogen, 
Barcelona, Spain) for 30 minutes at 4°C with rotation. The supernatant was 
recovered and incubated with immunoprecipitation antibody against the Myc tag 
(Cell Signaling, Danvers, MA, USA), followed by overnight rotation at 4°C. The 
next day, protein G beads were added to the lysate-antibody complex for 3h with 
rotation at 4ºC. The beads were washed three times with IP buffer and then 
incubated with whole mouse brain (WT) lysates for an additional 4h with rotation at 
4ºC. Beads were washed for the last time, boiled in protein sample buffer and the 
supernatant was loaded onto a SDS–PAGE (4-12% NuPAGE Bis-Tris Gel, 
Invitrogen), followed by Coomassie staining.  
 
Mass Spectrometry Analysis 
Disclaimer: The mass spectrometry analysis was performed in the Bioanalytic 
mass spectrometry facility at the Max Planck Institute for Biophysical chemistry, 
Goettingen.  
After protein separation on a SDS–PAGE (4-12% NuPAGE Bis-Tris Gel, 
Invitrogen), the entire lane of the Coomassie blue-stained gel was cut into 23 
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55 mM IAA for 20 min at 26°C and digested with modified trypsin (Serva) overnight 
at 37°C. Tryptic peptides were injected into a C18 pre-column (25 mm, 360 µm 
o.d., 150 µm i.d., Reprosil-Pur 120 Å, 5 µm, C18-AQ, Dr Maisch GmbH) at a flow 
rate of 10 µl/min. Bound peptides were eluted and separated on a C18 capillary 
column (12 cm, 360 µm o.d., 75 µm i.d., Reprosil-Pur 120 Å, 3 µm, C18-AQ, Dr 
Maisch GmbH) at a flow rate of 300 nl/min, with a gradient from 5 to 36% ACN in 
0.1% formic acid for 50 min using an Agilent 1100 nano-flow LC system (Agilent 
Technologies) coupled to a LTQ-Orbitrap Velos hybrid mass spectrometer 
(Thermo Fisher). The mass spectrometer was operated in the data-dependent 
mode to automatically switch between MS and MS/MS acquisition. Survey MS 
spectra were acquired in the Orbitrap (m/z 350–1600) with the resolution set to 
30,000 at m/z 400 and automatic gain control target at 5 × 10E5 ions. The fifteen 
most intense ions were sequentially isolated for CID MS/MS fragmentation and 
detection in the linear ion trap. Ions with single and unrecognized charge states 
were excluded. Raw data was analyzed with Mascot search engine for peptide 
and protein identifications. 
 
Viral transduction of H4 cells and selection 
H4 cells were plated in a 12 well plate with a low confluence (approximately 
20%). The day after they were transduced with LRRK2 lentivirus (LV-CMV-eGFP-
LRRK2-wt), a kind gift from Dr. Veerle Baekelandt (University of Leuven). Cells 
were monitored daily, via fluorescence microscopy, to check for LRRK2 
expression, which they start to express after three days of transduction, reaching 
maximum levels of expression after five days. Confluent cells were then re-plated 
into a 10 cm dish and after three days in culture were split. LRRK2 expressing 
cells were sorted by green fluorescence. Sorted LRRK2-expressing cells were 
kept in culture to proceed with immunostaining for phosphorylated LRRK2 (pS935, 
Epitomics) and with the Elastic E modulus analysis. 
 
Microscopy and Elastic E modulus analysis  
Cell probing was performed with an indention experiment. The cantilever with 
an attached sphere at the end pushes the cell surface until a certain force set point 
is reached, then the cantilever is withdrawn to the starting point. The interpretation 
of AFM-based indentation tests is dependent on the used theoretical model for 
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contact mechanics to determine Youngs modulus. It has been shown 
experimentally that for indentations of less than 600nm and spherical indenter 
geometry, the Hertz contact model is regarded as valid to derive Youngs modulus 
in bio material AFM experiments [36]. Youngs modulus (E) is derived from the 




Cell indentation is computed from the displacement of the z-piezo (z) minus the 
bending (b) of the cantilever (Figure 2). The sphere radius (Rb) and the Poissons 
ration (υ) were defined respectively for Rb=2.5µm and υ=0.4 [39]. 
 
Figure 2. Schematic representation of the cantilever 
deformation during a force distance experiment, using 
a spherical cantilever probe.  
The blue area represents a cell and the force is created by 




Distribution of the indenting load over several µm² area, averages the contribution 
of multiple cytoskeleton fibres and makes the contact analysis more accurate. 
Therefore, we used a cantilever with a borosilicate glass sphere with a radius of 
2.5 µm. The nominal spring constant of this cantilever is k= 0:035N/m. To ensure 
indentation of the cytoskeleton, we fitted the Hertz model in the range from 100nm 
to 500nm indentation - the higher border is to ensure the appropriate use of the 
model. The associated force borders lie within the range of 150pN to 1nN, the 
upper border marks the set point. Indentation speed was chosen at 5 µm/s [13]. 
Every cell was pushed three times at three different positions in the middle, 
between nucleus and the outer cell peripheries. The global cell value is the mean 
of the three pushes (Figure 3). 










Figure 3. (A) Graphic representation for fitting a force vs. indentation f(dz) curve with the 
Hertz model. (B) Graph from indentation experiments on the three different fluorescence 




5.3.1 Network of protein interactions  
The Mass Spectrometry (MS) analysis was performed after the IP/Pull Down 
assay of LRRK2 in mouse brain lysate with the goal of identifying candidates of 
LRRK2 protein interactors. The resultant list was carefully examined and only hits 
identified with more than 2 unique peptides were considered for subsequent 
analysis. The final list of hits, with approximately 360 candidates, was analysed 
using the STRING software [9] which revealed a complex network of protein 
interactions, based on documented and predicted results (Figure 4). The proteins 
are represented by gene name and the LRRK2 gene is located in the centre of the 
network, directly connected with four genes: SNCA, MAPT, HSP90 and CSE1L. 
 
5.3.2 Gene Ontology Analysis 
Gene ontology (GO) is a powerful approach used to predict how gene 
products behave in a cellular context. The GO analysis of the LRRK2-interactors 
network is very useful to highlight biological processes, cellular components and 
molecular functions where LRRK2 and its interactors may be involved. Using 
STRING software, the hits were organized in three categories: cellular 




































































































































































































































This category represents components of a cell, which may be an anatomic 
structure (e.g microtubule or mitochondria) or a gene product group (e.g 
proteasome complex or ribosome). Twenty of the most represented and 
statistically significant cellular components in the LRRK2-interaction network are 
summarized in table 1, and scored by the number of genes that correspond to 
each cellular component. Diverse cellular components are represented in the 
selected list. The most represented components are related to cytosolic structures 
like intracellular organelles, mitochondria, cytoskeleton and microtubule 
components and also to proteasomal and macromolecular complexes. 
 
Table 1. GO - Cellular Components. Selected list of the most represented cellular 
components, in the LRRK2-interaction network. The list shows the number of genes 






Cellular Components Number of Genes p-value Gene Examples
Cytosol 73 8.78E-2 AP1S1; PRKCG; CAMKK1; EEF1A1
Intracellular organelle part 58 1.48E-2 ANK1; DNM1L; RPL31; DNM1L
Macromolecular complex 38 1.04E-2 DNM1L; ROL11; STXBP1; HNRPR
Intracellular non-membrane-bounded organelle 28 5.12E-2 CBX3; CCT8; DYNC1H1; VDAC2
Organelle membrane 19 7.05E-2 LRRK2; SNCA; MATR3; SYT2;PHB2
Mitochondria 17 6.38E-3 ATP50; DNM1L; SEPT4; MT-CO2
Cytoskeletal part 14 2.06E-2 CCT8; TPM1; DPYsL3; DHX9
Ribonucleoprotein complex 13 1.08E-4 RPL7A; RPS16; ILF2; ACTN4
Cell projection 12 3.84E-3 STX1A; DPYSL3; SNCA; LRRK2
Cytoplasmic vesicle 12 5.22E-3 SNAP23; STXBP1; MYO1E; SNCA
Neuron projection 11 2.2E-3 DPYSL3; SNCA; LRRK2; MYO5A
Mitocondrial envelop 10 6.3E-2 PHB2; IQGAP1; DNM1L; ATP50
Mitochondrial membrane 10 6.3E-2 LRRK2; DNM1L; PHB2; ATP5B
Ribosomal subunit 8 1.03E-4 RPL4; RPS16; RPL11; RPL38
Actin cytoskeleton 8 6.4E-3 IQGAP1; SNCA; MYO6; DPYSL3
Clathrin-coated vesicle 7 2.32E-2 RAB3A; AP1S1; SYT1
Microtubule 5 9.92E-3 CCT8; DYNC1H1; DCTN1; DNM1L
Growth cone 4 6.3E-2 SNCA; MYO5A; DPYSL3; SNAP25
Synapse part 3 7.37E-2 CNTN2; SNCA
Proteasome complex 2 2.28E-2 VCP; PSMB3




The biological process category represents a collection of molecular events 
with a defined beginning and end. Different from the molecular function category, 
in general, the biological processes imply more than one distinct step. 
Twenty of the most represented and statistically significant biological 
processes within the LRRK2-interaction network are summarized in Table 2 and 
scored by the number of genes corresponding to each biological process. Diverse 
bilogical processes are also represented in the selected list and the most 
represented relate to cell transport, organization and differentiation, as well as 
regulation of biological quality, synaptic transmission and secretion. 
 
Table 2. GO - Biological Processes. Selected list of twenty of the most represented 
biological processes in the LRRK2-interaction network. The list shows the number of 







Biological Processes Number of Genes p-value Gene Examples
Cell Transport 59 6.6E-6 RAB1A; ANK1; EPB41L3; RPL11; RPL31
Cellular localization 40 1.16E-10 ANK1; ACTN4; YWHAH; RPL11; RPL31
Cellular component organization or cell biogenesis 40 1.43E-3 MYO1E; HSPA9; DCTN1; RAB11B;VIM
Cellular nitrogen compound metabolic process 34 5.3E-3 LRRK2; VCP; MYH9; RAB7A; RAB1A
Intracellular transport 29 6.77E-9 THOC4; SNAP23; RPN1;RPL18A;ATP5O
Regulation of biological quality 28 1.23E-2 ACTN4; RAD50; YWHAH
Nervous system development 24 1.31E-4 NCKAP1; DCTN1;MAP2K1; COL4A1
Cell differentiation 21 6.73E-3 ANK1; ANK2; CRMP1
Protein transport 18 7.73E-6  RPL31; RPL4; RPL11; RPS13
Neuron differentiation 17 3.24E-5 CRMP1; ANK1; MAP2K1; COL4A1
mRNA metabolic process 17 7.29E-5 HNRNPK; FUS; DHX9; TUT1; PSMB3
Regulation of cellular component organization 17 3.01E-2 STXBP1; DNM1L; SNCA; LRRK2; PHB
Vesicle-mediated transport 16 3.87E-4 RAB7A; ACTN4; ACTN1; ANK1
Neuron development 16 3.05E-5 CFL1; CNTN2; MYL6; CACNB3; CRMP1
Synaptic transmission 13 2.73E-3 GLUL; NSF; MYO6; PRKCG; CAMKK1
Secretion 13 2.54E-5 NSF; ANK1; ACTN1; ACTN4
Protein targeting to membrane 12 2.94E-7 SAMM50; ANK1; RPL4; RPS13; RPN1
Ribonucleotide metabolic process 11 4.16E-4 LRRK2; VCP; RAN11B; ATP50; MYH9
Protein localization to endoplasmic reticulum 11 2.64E-7 ANK2; RPL31; RPL11; RPS13; RPL18
Oxidation-reduction process 11 9.33E-3 IQGAP1;STXBP1; STX1A; SNAP25




Molecular function generally corresponds to activities, such as catalytic or 
binding activities, that occur at the molecular level. They can be the result of 
individual gene products, but some activities are performed by the combinations of 
gene products. In order avoid confusion with/between gene product name, many 
molecular functions are appended with the word "activity". Again, in table 3 is 
listed twenty of the most represented and statistically significant molecular 
functions in the LRRK2-interaction network, scored by number of genes 
corresponding to each molecular function. Also, in this category a variety of 
molecular functions are described. Thus, the two most represented groups are 
enzymatic activities (pyrophosphatases, hydrolases, ATPase, GTPase) and 
structural molecular activities (microfilaments activity, actin and cytoskeletal 
protein binding). 
 
Table 3. GO - Molecular Function. Selected list of twenty of the most represented 
molecular functions in the LRRK2-interaction network. The list shows the number of genes 
belonging to each molecular function, the statistical analysis and some gene examples. 
 
 
Molecular Function Number of Genes p-value Gene Examples
Enzyme binding 16 5.96E-2 TUT1; YWHAH; DNM1L; ANK1; EEF1A1
Nucleoside-triphosphatase activity 14 4.76E-6 CCT8; LRRK2; RAB7A; RAB1A; MYL6
Pyrophosphatase activity 14 9.62E-6 DYNC1H1; RAB11B; LRRK2; ATP50
Hydrolase activity, acting on acid anhydrides 14 9.62E-6 RAB1A; RAB7A; MYL6; CCT8; RAD50
Structural molecule activity 13 3.25E-4 MAP1B; TPM1; ARPC3; MATR3; SPTA1
RNA binding 11 1.34E-3 TARDBP; ILF2; RSP13; RPL4; TUT1
ATPase activity 9 6.6E-5 MYH10; MYO1E; CCT8; MYL6; MYH9
Cytoskeletal protein binding 9 1.05E-2 SNCA; LRRK2; ACTN4; MYO1E; ANK1
GTPase activity 8 1.52E-4 LRRK2; RAB7A; RAB1A; SEPT4; RAB11B
Structural constituent of cytoskeleton 6 2.87E-4 VIM; NEFM; TPM1; ARPC3; ANK1
Actin binding 5 1.25E-2 MYO1E; MYO6; SPTA1; TPM1; ACTN4
Ion chanel binding 5 2.33E-2 ACTN1; LRRK2; YWHAH; ANK2; HOMER1
Microfilaments motor activity 5 6.3E-3 MYO6; MYO1E; MYH9
Protein homodimerization activity 4 2.32E-2 LRRK2; ACTN4; MYH9
Actin filament binding 4 4.23E-3 ACTN4; MYO1E; MYO6; SPTA1
ADP binding 4 2.33E-2 MYH9; MYH10; MYO6; ATP5D
Protein phosphatase binding 3 4.52E-2 IQGAP1; VCP; LRRK2
SNARE binding 2 1.3E-2 RAB11B; SYT1
Protein serine/threonine/tyrosine kinase activity 2 2.54E-2 LRRK2; MAP2K1
GDP binding 2 3.78E-2 RAB11B; RAB7A
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Kyoto Encyclopedia of Genes and Genomes Pathways 
The Kyoto Encyclopedia of Genes and Genomes (KEGG) is a database 
resource that comprises a collection of pathway maps representing knowledge of 
molecular interactions and reaction networks. It is essential for understanding 
high-level functions and utilities of a biological system, such as the cell or the 
organism, especially in large-scale molecular datasets, generated by high-
throughput experimental approaches. The most highly represented and statistically 
significant KEGG pathways in the LRRK2-interaction network, were scored by the 
number of genes, corresponding to each pathway (Table 4). These results show 
that several pathways associated with neurodegenerative diseases such as PD, 
Huntington’s and Alzheimer’s, can be identified in the LRRK2-interaction network. 
Genes directly and indirectly linking LRRK2 to these pathways are highlighted in 
the LRRK2-network, where the connection of LRRK2 with central genes like 
SNCA, MAPT or Rab7a is depicted (Appendix Figure 5.1, 5.2, 5.3). 
The LRRK2-interaction network also includes genes that confirm the 
involvement of LRRK2, with pathways related with the ribosome, oxidative 
phosphorylation and cytoskeleton regulation. Some of these genes, like RPS 
genes related with the cellular structure of the ribosomes and ATP genes, related 
with the supply of energy in the cell are highlighted in appendix figures 5.4 and 
5.5. 
 
Table 4. KEGG Pathways. Selected list of eleven of the most represented KEGG 
Pathways in the LRRK2-interaction network. The list shows the number of genes 
belonging to each pathway, the statistical analysis and some gene examples. 
KEGG Pathways Number of Genes p-value Gene Examples
Ribosome 14 1.33E-8 RPL32; RPL7A; RPS16, RPL11
Regulation of actin cytoskeleton 12 2.8E-2 IQGAP1; MYH19; NCKAP1; ACTN1/4
Parkinson's disease 11 2.31E-5 SNCA; LRRK2; UNA1; ATP5B
Huntington's disease 9 6.34E-3 DCTN1; COX4I1; MT-CO2; ATP5B
Oxidative phosphorylation 8 3.75E-3 COXaI1; NDUFS6; ATP5B
Alzheimer's disease 8 1.5E-2 MAPT; SNCA; NDUFS6; ATP5-D
Spliceosome 6 7.78E-2 DMX15; HNRPK; HNRPM; HNRPA3
Citrate cycle (TCA cycle) 4 2.34E-3 DLAT; IDH3B; MDH1; FM
SNARE interactions in vesicular transport 4 3.68E-3 SNAP23; SEC22B; SNAP25; STX1B
Glycolysis / Gluconeogenesis 4 2.83E-2 DLAT; PFKM; HK1; PGAM1
Adherens junction 4 5.3E-2 ACTN1; ACTN4; IQGAP1; ACTG1
Galactose metabolism 2 8.22E-2 PFKM; HK1
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5.3.3 The effect of LRRK2 expression on the mechanical properties of the 
cell  
 
Disclaimer: The AFM and TIRFM experiments were performed by Kai Bodensiek 
from Atomic Force Microscopy-biomechanics laboratory, Georg-August University, 
Göttingen. 
 
The previous analysis of the LRRK2-interactors enabled us to identify 
proteins, and groups of proteins, that directly or indirectly interact with LRRK2. We 
found that several LRRK2-interactors are related to cytoskeleton structures, like 
actin, tubulin and myosins. The GO analysis highlighted cellular components and 
molecular functions such as microtubules and other parts of the cytoskeleton, 
proteins binding cytoskeleton, structural constituents of cytoskeleton and proteins 
involved in microfilaments motor activity.  
The structural and mechanical properties of a cell are important parameters 
that influence its regular function, reflecting its health conditions. The stiffness of 
eukaryotic cells is a parameter conditioned by several forces from membrane 
tension but mainly determined by the cytoskeleton structure, that is constituted by 
several polymeric networks including actin, microtubules and intermediate 
filaments [10]. Atomic Force Microscopy (AFM) is a method widely used to study 
the mechanical characteristics of a cell, through the measurement of the cell's 
visco-elastic properties [11,12].  
Given the documented effect of LRRK2 on microtubules [13, 14], we decided 
to explore the mechanical effect of LRRK2 on cells at the structural level. For that, 
we expressed LRRK2 in a human neuroglioma cell line (H4), and performed cell 
indentation experiments with AFM, to quantify changes in cytoplasmic 
crosslinking, aggregation, depolymerisation, and polymerisation. To better analyse 
an isolated cell in culture, we used a setup in which the AFM is combined with a 
Total Internal Reflection Fluorescence Microscope (TIRFM). TIRFM was used in 
bright field illumination to localize the different phenotypes, which could be 
targeted with the AFM. 
 
5.3.4 Different LRRK2 distribution patterns result in different cell stiffness 
 
Analysing H4 cells transduced with viruses encoding for LRRK2-GFP via 
fluorescence microscopy, we noticed a mixture of different distribution patterns of 
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the fusion protein, presenting several cytoplasmic structures. Interestingly, after 
immunostaining these cells with a phospho-specific LRRK2 antibody (at S935 
residue), we verified that these structures, composed by LRRK2, are also enriched 
in phosphorylated LRRK2 (Figure 5). In order to closely analyse these different 
patterns, we distinguished LRRK2 expressing cells into three classes: diffuse 
expression, dotted expression and filamented expression (Figure 6). 
Figure 5. Expression of eGFP-LRRK2 in H4 cell line.  
H4 cells transduced with eGFP-LRRK2 lentivirus, stably expressing LRRK2. The 
fluorescent microscopic images show the different distribution patterns of LRRK2, with 
different shapes of cytoplasmic structures, that the immunostaining revealed to be highly 
phosphorylated at residue S935. 
 
These cells were analysed by linking their viscoelastic behaviour to the 
grouped LRRK2-expression patterns. The chosen experimental parameters (see 
methods) allow for approximation of the cell as an elastic body whereby we were 
able to use the elastic modulus, known as Youngs modulus (E), as parameter for 
its characterization [15]. A detail of the different cytoplasmic structures present in 
the three different cell classes is shown on figure 6. 
The results show that different LRRK2 distribution patterns result in 
differences in the elastic modulus, allowing us to characterize each cell classes 
according to its mechanical behaviour. Thus, cells with a diffuse pattern are the 
stiffest, followed by cells with filamented LRRK2 expression. Cells with a dotted 
pattern have lowest levels of stiffness and are similar to cells only expressing the 
GFP tag or the un-transduced H4 cells (Figure 7). Statistical analysis of the results 
shows that cells with a diffuse or filamented pattern possess a significantly higher 
E modulus than cells with a dotted expression. Although cells with a diffuse pattern 
are stiffer than cells with filamented pattern, this tendency is not statistically 
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Figure 6. Different distribution patterns of LRRK2 in H4 cells. H4 cells expressing 
LRRK2 were classified according to their LRRK2 distribution patterns in: diffuse, dotted 
and filamented. In the lower row of pictures there is a detail of the cytoplasmic 
environment characteristic of each class. The microscope measurements of several cells 
per each class, like the ones exemplified in figure 5, were analysed using the Elastic E 
modulus. 
 
Figure 7. LRRK2 distribution patterns distinguished by Elastic E modulus analysis. 
Cells from the three different classes of LRRK2 distribution, and the two controls (H4 and 
GFP-H4), were analysed by combined AFM/TIRFM and their mechanical properties were 
quantified by the Elastic E modulus. The analysis distinguished cells with LRRK2 diffuse 
distribution as stiffer ones, followed by cells with LRRK2 filamented distribution - both 
differed significantly from control samples (H4 and GFP-H4). Dotted expression cells have 
a similar stiffness to control cells, being significantly different from diffused cells (p<0.05) 
and tendentiously different from filamented cells (p<0.1). Diffuse distribution (N= 13); 
filamented distribution (N=16); dotted distribution (N= 18); H4 cells (N=50); GFP-H4 
(N=50). Significance results from T-test: **p< 0.01 and * p<0.05.  
 
       Uniform            Dot-like             Worm-like                                GFP Diffuse tted Filamented  





The identification of LRRK2 interactors is crucial to place the protein in 
known biochemical pathways, allowing a better understanding of its physiological 
function and associated pathology. To fulfil this goal, a variety of LRRK2 high-
throughput studies like yeast two-hybrid screens, mass spectrometry, pull-down 
assays and genome-wide mRNA expression screens, have been performed alone 
or in combination. The identified LRRK2 interactors and substrates have 
implicated the protein in a variety of pathways and biological processes. Some of 
those are cytoskeleton dynamics, protein translation, cell growth and 
differentiation, cell signalling, among many others. 
In this study we used a sequential Co-IP followed by mass spectrometry in 
order to identify novel LRRK2 interactors. Within the vast list of potential LRRK2-
interactors obtained, we could confirm the presence of some already described 
protein interactors, such as HSP90/70 [16,17], α-β-tubulin [18, 19], Rab5 [20, 21], 
14-3-3 [22, 23], vimentin and clathrin [24]. This proved the robustness of the 
experimental approach used. 
Through gene ontology analysis of the LRRK2-interactors network, we 
confirmed that LRRK2 is a multifaceted protein, involved in a variety of molecular 
functions and biochemical pathways. As a kinase, LRRK2 is naturally involved in 
several enzymantic reactions. LRRK2 has also a role in intracellular organelles (as 
mitochondria), in cytoskeleton and microtubule components, in cell transport, cell 
quality control and cell organization/differentiation.  
As expected, LRRK2 is present in the PD pathway but, interestingly, also in other 
neurodegenerative diseases like Alzheimer’s and Huntington’s disease. This 
demonstrates that the important role of LRRK2 and it protein interactors is not only 
limited to PD. 
LRRK2 is also present in pathways involving the ribosome, oxidative 
phosphorylation and cytoskeleton regulation. This suggests that LRRK2 plays a 
role in important cell pathways as protein synthesis, cellular respiration and 
cytoskeleton organization and rearrangement. 
Within the LRRK2-interactors network, we highlight the presence of α-
synuclein and Tau proteins. These two central proteins in PD and AD diseases 
were identified as LRRK2 interactors and potential substrates [25-28], and their 
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interaction with LRRK2 has been extensively explored in chapters 3 and 4 of this 
thesis. 
The role of LRRK2 on the cytoskeleton is one of the most well accepted 
functions of the protein, supported by the discovery of several protein interactors 
linked to microtubule dynamics. LRRK2 interaction with α/β-tubulin was confirmed 
in different studies. It was shown that LRRK2 mutants reduce neurite outgrowth 
and cause an accumulation of hyperphosphorylated Tau protein, compromising 
the microtubule dynamics [19, 29, 30, 31]. This dynamics might also be influenced 
by the interaction of LRRK2 with actin and actin-related proteins [32]. The link 
between LRRK2 and microtubules is further supported by the interaction with 
proteins like EF1A, moesin (a member of ERM family) and DVL1/2/3 proteins. 
These proteins are respectively related to the stability of microtubules, the 
regulation of anchoring of the actin cytoskeleton to the plasma membrane and 
axon guidance and synapse formation [33-35]. 
Knowing that LRRK2 has an important influence on microtubules and 
consequently on cytoskeleton dynamics, we decided to explore how this could 
affect the mechanical properties of the cell. The results from cell indentation 
experiments, using a combined AFM/TIRFM technique, confirm that different 
LRRK2 distribution patterns contribute to differences in cell stiffness. Thus, the 
diffuse LRRK2 distribution pattern is the one presenting the stiffest cells. 
Curiously, the dotted pattern is the only one in which stiffness was not altered 
when compared to control samples. The previously described role of LRRK2 on 
microtubule networks, allows the speculation about these LRRK2 distribution 
patterns. Thus, in the diffuse pattern LRRK2 might be spread throughout the entire 
cell, interacting with the microtubule-related proteins and compromising 
cytoskeleton dynamics by increasing stiffness.  
One of the pathological hallmarks of PD is the presence of inclusions 
composed of misfolded proteins in remaining live neurons and LRRK2 is often 
identified as one of the components of the inclusions [25]. The role of these 
inclusions has been extensively discussed and whether they are toxic to the cells 
or confer protection is still unclear [36, 37]. In our cell model, the LRRK2 dotted 
distribution pattern could be compared to the presence of these cytoplasmic 
protein inclusions, and we concluded that cells presenting this pattern have the 
same stiffness compared to the control cells. Thus, we can speculate that 
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cytoplasmic inclusions may be a defensive mechanism for cells to deal with a high 
expression of intracellular LRRK2. Therefore, the formation of these inclusions 
may be a way for cells to pack an excess of free cytoplasmic LRRK2, which might 
be interacting with microtubules and impairing the normal cytoskeleton dynamics 
of the cell. To confirm this theory, more experiments need to be performed, 
particularly to better characterize these dotted LRRK2 inclusions, evaluate the 
kinetics of their formation and compare the viability of cells presenting these 
distribution patterns. The interesting LRRK2 distribution patterns obtained in this 
model could still be useful to test the effect of several chemical compounds in the 
inclusion formation, finding an analogy with what could happen in the formation of 
LBs.  
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Chapter 6. General discussion and conclusions 
 
Since its discovery in 2004, LRRK2 is recognized as the most frequently 
mutated protein associated with familial forms of PD.  
Although numerous efforts are underway in order to better understand the 
role of this protein in PD, the function of LRRK2 is still not fully understood. LRRK2 
is a large and multi-domain protein presenting double enzymatic activity, it works 
as a kinase, as well as a GTPase. LRRK2 has the propensity to interact with 
several proteins or protein-complexes, suggesting that it is involved in several 
cellular mechanisms.  
A solid understanding of the function(s) of LRRK2 is crucial in order to 
decipher the basic mechanisms compromised during the onset and development 
of PD. In turn, this would serve as the basis for the development of novel 
strategies for therapeutic intervention. Thus, this project had the goal of gaining 
new insight into the function and dysfunction of LRRK2 in PD. To achieve this 
goal, we focused on identifying new LRRK2-interacting proteins, highlighting the 
cellular mechanisms and pathways where it could be involved. We explored the 
interaction of LRRK2 with two other central players in neurodegenerative 
disorders: α-synuclein and Tau. 
 
6.1 Implications of the interaction of LRRK2 with α-synuclein and Tau 
α-synuclein was the first protein associated with familial forms of PD. 
Together with LRRK2, it is reported as being the cause of dominantly inherited 
forms of the disease. α-synuclein is a pre-synaptic protein highly expressed in the 
brain and one of the main components of the LBs, a pathological hallmark of the 
disease, where it appears mostly in its phosphorylated form [1,2]. As LRRK2 is a 
kinase and its most frequent mutation, G2019S, is responsible for a toxic gain of 
function, it was hypothesized that α-synuclein might be a direct LRRK2 substrate. 
In this context, LRRK2 would be responsible for the hyper-phosphorylation of α-
synuclein in a disease context [3]. Although this idea was first put forward in 2009, 
the results were not conclusive, mostly due to the lack of specific and reliable 
LRRK2 antibodies at the time. Since then, these results were not verified in 
subsequent reports [4,5]. More recently, we revisited this question, taking 
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advantage of the new generation of LRRK2 antibodies developed by the Michael 
J. Fox Foundation. In chapter 3, we demonstrate the interaction between 
endogenous LRRK2 and α-synuclein in mouse brain samples and in a cellular 
model. Interestingly, we demonstrate that the hyperactive LRRK2 mutant 
(G2019S) does not interfere in this interaction. Moreover, in human PD brains, we 
showed a positive correlation between the levels of LRRK2 and α-synuclein and, 
even more strikingly, with widespread S129 α-synuclein phosphorylation. Still, in 
human brain tissue, it was possible to detect the co-localization of these two 
proteins in neurons, prior to the formation of LBs and also within these inclusions. 
The relation between LRRK2 and the formation of α-synuclein inclusions was also 
confirmed in a cell model where KD of LRRK2 promoted a decrease in the size of 
those inclusions [5]. Although we are still not able to determine whether α-
synuclein is a direct interactor and/or substrate of LRRK2, the published evidences 
highlight that the two proteins indeed have common pathways [6-8]. LRRK2 
changes the aggregation pattern of α-synuclein in a cell model and in PD brains, 
the levels of both proteins are directly correlated, and the two proteins co-localize 
in LBs, as well as in neurons without inclusions. This allows us to speculate that 
LRRK2 might play a role upstream of α-synuclein aggregation and 
phosphorylation.  
Additional work is still necessary to confirm which pathways and proteins are 
affected by LRRK2-induced accumulation of α-synuclein, and whether this is a 
toxic or a survival mechanism for PD cells. It will be interesting to use models that 
combine LRRK2 with other proteins known to be involved in α-synuclein 
aggregation, for instance, synphilin-1 or a chaperone-like protein, such as 14-3-3 
[9-11]. 
 
Tau is the main component of the neurofibrillary tangles characteristic of AD 
patients. It is a predominantly neuronal protein that binds and stabilizes the cellular 
microtubule network, essential in a number of cellular processes. Tau mutations 
have been related to several neurodegenerative disorders, known as tauopathies, 
characterized by the presence of hyperphosphorylated and insoluble aggregated 
forms of Tau in different brain regions. Several Tau mutations have also been 
pinpointed as risk factors for PD and, in fact, insoluble accumulation of Tau and 
Tau tangles can be observed in PD brains. The implication of Tau in PD is also 
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highlighted by its relationship with α-synuclein and LRRK2, two central proteins in 
PD [12-15]. 
In chapter 4 we prove that Tau interacts with LRRK2. Moreover, we 
demonstrate that increased levels of LRRK2 promote the accumulation of 
intracellular Tau, by interfering with its proteasomal degradation. We raised the 
hypothesis that this impairment may occur by a direct LRRK2 blockade of the 
proteasome or by an interaction with Tau, compromising its degradation. Although 
further experiments need to be done to clarify the mechanism behind this effect, 
we can speculate how LRRK2 interacts with Tau. The interaction can occur either 
directly or indirectly, via other common interactors, like microtubule-related 
proteins, influencing its intracellular accumulation and posttranslational 
modifications [16,17]. Accumulation of cytoplasmic Tau promotes the formation of 
HMW-Tau species that are considered inducers of fibrillar and toxic forms of the 
protein, increasing the release of Tau to the extracellular space. Along with these 
results, evidence for the presence of Tau tangle pathology in LRRK2 transgenic 
models were reported, as well as an increase of Tau aggregation and 
phosphorylation in a taupathy model due to LRRK2 expression [18-20].  
The fact that Tau accumulation seems to occur independently of the LRKK2 
kinase activity, supports the idea that Tau may not be a direct substrate of LRRK2, 
as it was previously suggested [19,20]. Thus, LRRK2 could act upstream of Tau 
phosphorylation, through the ERK pathway, for example [21]. Therefore, LRRK2 
seems to play an important role in the homeostasis of Tau levels and, 
consequently, on Tau posttranslational modifications. This is supported by the 
widely accepted idea that intracellular accumulation of Tau results in increased 
aggregation and phosphorylation of the protein in the brains of AD and PD patients 
[22,23]. It can be speculated that this effect may be at the genesis of Tau 
cytoplasmic toxic fibrillar forms. Further, these fibrillar Tau species can be 
released into the intercellular media and taken up by neighbouring cells, explaining 
the spreading mechanism that happens in taupathies [24,25]. LRRK2 is also a 
protein degraded by the proteasome, thus, it will be interesting to explore the 
effect of Tau on LRRK2 levels. Further experiments will be required to identify 
which pathways and proteins are involved in this complex accumulation/release 
process.  
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Altogether, these results contribute to a better understanding of the 
interaction between LRRK2 and two central proteins in PD and AD, α-synuclein 
and Tau. In parallel, it raises new pertinent questions regarding the role of LRRK2 
on the molecular mechanism behind the neurodegenerative process. Answering 
these questions will help to clarify the molecular mechanism behind the complex 
process of protein accumulation, aggregation and spreading. The increased 
knowledge in these processes, common among several neurodegenerative 
disorders, will shed light into possible targets for therapeutic intervention. 
 
6.2 LRRK2-interacting protein network and its particular role on 
cytoskeleton dynamics 
LRRK2 is a complex and multifunctional protein likely to be involved in a 
variety of cellular mechanisms; however its defined function, and particularly in a 
disease context, is still poorly understood. In chapter 5, we aimed to determine the 
cellular mechanisms and pathways where LRRK2 may be involved.  For this, we 
applied a combined method of LRRK2 sequencial Co-IP assays, followed by Mass 
Spectrometry and bio-informatics analysis. 
The list of candidates obtained, confirmed several LRRK2-interactors 
identified using other approaches. These interactors include HSP90/70 [26,27], α-
β-tubulin [28,29], Rab5 [30,31] and 14-3-3 [32,33], validating the robustness of our 
technical approach. Moreover, the presence of α-synuclein and Tau in the list of 
interactors supports the claims in chapter 3 and 4 of this thesis, where we 
explored the interaction of LRRK2 with these two proteins.  
The analysis of the protein-interacting networks identified LRRK2 as a 
protein that is involved in a variety of cellular biological processes, such as 
transport, respiration, differentiation, quality control, oxidative phosphorylation and 
protein synthesis. These results corroborate previous reports regarding the 
multifunctionality of LRRK2. This protein is involved in different cellular 
mechanisms and pathways, not only because of it kinase and GTPase enzymatic 
functions, but also resulting from the discovery of multiple key LRRK2-interactors 
[34, 35]. 
The role of LRRK2 on microtubules and the cytoskeleton is one of the most 
accepted functions of the protein, supported by the discovery of several protein 
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interactors related to microtubule dynamics [36-39]. The analysis of the obtained 
hits in chapter 5 corroborates this idea, in which LRRK2 is involved in several 
important microtubule and cytoskeleton-related cellular mechanisms. The 
experiments exploring the effect of LRRK2 on mechanical properties of the cell 
showed that different LRRK2 distribution partner contributes to differences in cell 
stiffness. Thus, cells with a diffuse LRRK2 pattern are the stiffest ones and cells 
with a dotted pattern do not experience alterations in stiffness. Therefore, the 
dotted pattern observed, upon an increase of LRRK2 expression, could be a 
common pattern that occurs with increasing levels of other proteins. This pattern 
could even resemble the cytoplasmic protein inclusions observed in several 
cellular and animal models or even the Lewy bodies present in PD brains. The 
formation of these dotted inclusions may represent a defensive mechanism of the 
cell to pack the excess LRRK2, avoiding diffuse cytoplasmic accumulation, 
increasing cell stiffness and resulting in an impairment of cytoskeleton dynamics. 
Further experiments will be needed, to understand the biological relevance of 
altered stiffness in different LRRK2 distribution patterns, and the implications of 




PD is considered the second most frequent age-related neurodegenerative 
disorder, after Alzheimer’s disease. The tendency for increasing life span of the 
world population potentiates the occurrence of increasing propensities of PD 
cases. This ultimately culminates in a complex social/economical problem that 
needs to be addressed from a multifaceted perspective. Despite advances 
obtained in minimizing symptomatology and improving life quality of the patients, 
to date, there is no effective treatment for PD. In this context, it is urgent to deeply 
understand the molecular and cellular mechanisms that are compromised during 
the neurodegenerative process. This will be crucial to identify effective therapeutic 
targets for finding a cure for PD and other similar neurodegenerative diseases. 
The main goal of this thesis was to gain insight into the function of LRRK2 
protein, as the most frequently mutated protein associated with dominant forms of 
PD.   
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The important role of LRRK2 in the molecular underpinnings of PD and AD 
was confirmed by its interaction with α-synuclein and Tau, and it influences on 
their biochemical characteristics and cellular distribution. Therefore, LRRK2 is an 
important protein for the cellular protein homeostasis, and so related with several 
complex biochemical pathways, wich are usually compromised in PD or AD, but 
also other neurodegenerative disorders. Moreover, LRRK2 reveals to be a 
multifunctional protein, implied in several crucial cellular mechanisms, related to 
the pathogenesis of PD and which should be further explored. 
The results obtained in this work, provide several insights into the complex 
role of LRRK2 in PD-related mechanisms and also other neurodegenerative 
disorders. Consequently this will open new research venues, crucial for obtaining 
a more comprehensive level of understanding the interplay between these central 
neurodegenerative proteins. Ultimately, this knowledge will help to target important 
cellular mechanisms and pathways for therapeutic intervention. 
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Table 3.1. Table with details of clinical cases 
PD cases fulfilled the UK PD Society Brain Bank Diagnostic Criteria, were levodopa-
responsive and medicated throughout the disease course, and had no other significant 
neuropathological changes. Controls had no significant neuropathology and no evidence 
of neurological or psychiatric disease. The PD cases had a mean age of 79±9 y, mean 
disease duration of 15±4 y and a mean postmortem interval of 8.5±8 h. The controls were 
9 years older on average (mean age of 88±6 y, ttest p=0.02) and had a similar 
postmortem interval (mean of 10.5±5 h, ttest p=0.5). Because of the age difference, age 
was co-actored into all analyses, but the use of older controls ensured that in such cases 
Lewy pathology in late age would not have occurred. There was no difference in the sex 














Braak PD stage 
(0-VI) 
Control 1 79 M -- 8 -- 
Control 2 83 F -- 7 -- 
Control 3 85 M -- 9 -- 
Control 4 85 F -- 10 -- 
Control 5 86 M -- 15 -- 
Control 6 87 F -- 5 -- 
Control 7 88 M -- 9 -- 
Control 8 92 F -- 16 -- 
Control 9 93 F -- 21 -- 
Control 10 102 F -- 5 -- 
PD 1 66 M 12 6 V 
PD 2 69 M 17 5 V 
PD 3 72 M 9 4 IV 
PD 4 75 M 14 9 V 
PD 5 78 M 24 6 V 
PD 6 83 F 14 32 V 
PD 7 83 F 14 7 V 
PD 8 84 M 17 7 IV 
PD 9 90 M 15 5 V 
PD 10 91 F 10 4 IV 
 
 
Table 3.2. Sequences of the five LRRK2 shRNA  
(RNAi Consortium; Broad Institute, Ma, USA) 
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